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1Introduction
Coronary heart disease (CHD) is a major cause of death in many of the developed countries of the
world including Germany and the USA (1).  As many women die of this disease as men, but on
average, they do it about seven years later.  The disease is caused by atherosclerosis of the
coronary arteries, which progressively narrows the arteries until they become totally occluded.  At
that point in time, there is myocardial infarction (death of heart muscle), also known as a heart
attack.
Therapy for this disease includes coronary artery bypass surgery or balloon angioplasty to treat
the disease when it occurs.  An alternative approach is, of course, CHD prevention.  In this
regard, epidemiological as well as experimental studies have clearly shown that the major risk
factors for CHD, in addition to a sedentary lifestyle and diet high in saturated fat and cholesterol,
include: family history of premature heart disease (£ 55 years old in a male first degree relative
and £ 65 in a female first degree relative), advancing age (being a male ³ 45 or a female ³ 55
years old), high blood pressure, diabetes mellitus, cigarette smoking, elevated low density
lipoprotein (LDL) cholesterol (over 160 mg/dl, 4.1 mmol/L) and decreased high density
lipoprotein (HDL) cholesterol (less than 35 mg/dl or 0.9 mmol/L) (2-4).  The current view is that
with aging and hypertension, as well as diabetes and smoking, there is progressive damage to the
endothelial cells lining the arteries, causing excess deposition of LDL into the artery wall,
resulting in higher levels of “foam cells.”  The role of HDL appears to promote cholesterol efflux
from tissue, including the artery wall, and high levels of HDL cholesterol (HDL-C) have been
shown to be protective, while low levels of HDL-C have been shown to be a significant risk factor
for heart disease (5).
The cornerstone of prevention of CHD continues to be altering one's lifestyle, specifically diet and
exercise (2-4).  Prospective studies with diet, or diet and drug therapy associated with LDL
cholesterol (LDL-C) lowering have been shown to markedly reduce the risk of heart disease (6-
8).  Diet therapy is indicated in patients if their LDL-C levels are ³160 mg/dl in the absence of
heart disease risk factors, ³130 mg/dl in the presence of two or more risk factors as previously
mentioned, and ³100 mg/dl if the patient has established heart disease.  For patients with LDL-C
values even 30 mg/dl higher than those cut points as mentioned for diet, additional drug therapy is
indicated.  The US National Cholesterol Education Program (NCEP), however, has emphasized
that lifestyle modification should be the primary treatment in lowering cholesterol values, with
2drug therapy reserved for those patients where lifestyle modification is ineffective.  Modifications
contain dietary changes, regular aerobic exercise, and normalization of body weight.
With regard to dietary changes, the NCEP recommendations to reduce CHD risk for the general
population include restriction of total fat intake to £ 30% of daily calories, saturated fat to less
than 10% of daily calories, and dietary cholesterol to £ 300 mg/day (Step 1 diet).  For individuals
with elevated LDL-C levels, further restrictions for saturated fat to < 7% of daily calories and
dietary cholesterol to < 200 mg/day are emphasized (Step 2 diet).  However, the results of such
cholesterol lowering diets are variable.  When such diets are imposed on people and all the food is
given to them under controlled settings as compared to an average Western diet, reduction of
LDL cholesterol is generally in the order of 15-20%, but there is a wide variation in response to
such a diet, ranging from virtually no reduction to 50% reduction (9-13).  One factor clearly
affecting this variation in response is the genetic differences within various proteins involved in
lipoprotein metabolism.  In the free-living state, diet counseling by a dietitian generally results in
about a 5% reduction in LDL-C, largely because of decreased compliance (8).  An alternative
approach is for patients to go into a very intensive program where they actually live at a center
and have the food provided to them, such as at the Pritikin Longevity Center.  In this residential
program, patients are provided with a diet rich in food of plant origin and very low in fat,
saturated fat, and cholesterol.  In such a setting, significant reductions in LDL cholesterol,
triglyceride, glucose and body weight have been reported (13).  The question of course is what
the long-term effects of these diets are, and do the patients or clients stay on such programs when
they are back at home in the free-living situation.
A quantitative relationship has been established between changes in dietary intake of fatty acids
and cholesterol and the resulting serum cholesterol change (14-16).  Other mechanisms of
predicting HDL and LDL cholesterol response have been established.  These relationships are
well founded and predictable for groups (17-19); however, on an inter-individual basis, a striking
variability in serum cholesterol response to diet has been known for years (20).  Therefore, this
variability in response has been discussed in several previous reports (19, 21-23).  While in some
individuals, plasma cholesterol levels dramatically decreased following consumption of a low fat
diet, it remained unchanged in others.  Jacob et al. (22) demonstrated under a variety of controlled
dietary conditions that 3% were nonresponders, 9% were hyporesponders, and 64% responded
within 30% of prediction using the Keys-Minnesota equation.  The remaining 9% were considered
hyperresponders.  Furthermore, Katan et al. (20) described a consistency of response on intra-
individual basis.  In their study, they observed that hypo- and hyperresponders, based on their
3response to dietary cholesterol intake, remained in the same group, even though their diets were
modified several times.  This would indicate that lipid alterations induced by dietary intervention
might partly be controlled by genetic factors.  Animal experiments (24-27) already revealed that
response of serum lipoprotein to dietary modifications may have a strong genetic component.  In
humans, the evidence is still unclear, even though several gene loci have been suggested to be
involved in the individual lipid response to dietary modifications.  If such a genetic variability is
proven to be true, it could have a significant impact on the development and success of public
health policies and individual therapeutic interventions.
Several genes coding for apolipoproteins have been identified to be good candidates for
investigation regarding lipid variation and dietary response.  Apolipoproteins are structural
components of lipoproteins, which are primarily synthesized in the liver and intestine.  They play
an important role in the transport and redistribution of dietary and endogenously derived lipids in
the body (28-30).  Apolipoproteins, are also cofactors of enzymes involved in lipid metabolism
and ligands for cell surface receptors involved in lipoprotein uptake (28).  So far, several different
apolipoproteins, designated apo A-I, apo A-II, apo A-IV, apo B-48, apo B-100, apo C-I, apo C-
II, apo C-III, apo D, and apo E, have been found.  For most of those proteins, genetic variability
has been described in humans (29).  Some of these gene variations have been shown to be
responsible for abnormal lipid profiles, which may contribute to the pathogenesis of
atherosclerosis.  Therefore, studies of the impact of genetic variability at these gene loci on
plasma lipid levels and their interaction with other genes and environmental factors are of great
interest.
In the present study, we investigated specific common mutations at the apolipoprotein E, A-I, A-
IV, and lipoprotein lipase candidate gene loci, and their effects on plasma lipid levels at baseline
and after an intervention program including diet therapy and exercise.  Genetic variations at these
gene loci are frequent enough to have a potential impact not only on an individual's levels, but
also in the general population.
The following section includes an overview of each of those apolipoproteins and lipoprotein
lipase, as well as their gene polymorphisms investigated in this study.
Apolipoprotein E
Apolipoprotein (Apo) E polymorphism is supposed to rank among the major factors involved in
determining interindividual differences in the initiation and progression of atherosclerosis due to
4its influence on plasma lipoprotein concentrations.  Apo E circulates in the plasma as a protein
constituent of intestinally derived chylomicron remnants, hepatic derived very low density
lipoproteins (VLDL) and their remnants as well as a subclass of HDL (31).  When associated with
these lipoproteins, apo E serves as a ligand for the apo B,E-receptor and the LDL-receptor
related protein (LRP) (32-34).
The gene for apo E is located on chromosome 19 (35).  It is in close linkage to the genes for apo
C-I and C-II and more distantly linked to the gene for the LDL-receptor (36).  In humans, the
structural gene locus for plasma apo E is polymorphic (37-40): three common alleles, designated
as e2, e3, and e4 which code for three major apo E isoforms E2, E3 and E4, respectively.
Therefore, this polymorphism leads to six different phenotypes which have been distinguished by
isoelectric focusing (IEF) and immunoblotting (41): three homozygous (E2/2, E3/3, and E4/4)
and three heterozygous (E2/3, E2/4, and E3/4).  The isoforms differ from each other by a single
amino acid substitution.  While apo E3 contains a cysteine at residue 112 and an arginine at
residue 158, apo E2 contains two cysteines and apo E4 two arginines at each residue, respectively
(42,43).
Figure 1:  Apo E Alleles Caused by an Inter-Exchange of the Amino
Acids Arginine and Cysteine
Apo E Genotypes
ARG ARG
E4       
CYS ARG
E3       
CYS CYS
E2       
1 112 158 299
ARG: Arginine, CYS: Cysteine at Amino Acid Positions 112 and 158.
5As a result, apo E4 has one more positive charge compared to E3, and E2 has one less (44).
Considering that the receptor-binding site of apo E is located between residue 136 and 158, this
difference in charge is responsible for their different binding affinities for the LDL-receptor.
While E3 and E4 both carry an arginine at position 158, their ability to bind to the apo B,E
receptor is the same compared to the markedly reduced affinity (<1%) of E2 (45).  This reduced
binding capacity results in a slower clearance of apo E2 lipoproteins, which subsequently leads to
an up-regulation of the LDL-receptors.  Therefore, a majority of individuals with the E2 allele
have reduced serum cholesterol concentration (46).  However, 1-10% of individuals with the E2/2
genotype develop type III hyperlipoproteinemia (47), a condition characterized by the
accumulation in the plasma of triacylglycerol-rich lipoprotein remnants.  Such individuals have a
strong predisposition for the development of premature and accelerated atherosclerosis (48).
Apo E4, on the other hand, has an amino acid substitution at codon 112 which appears to reduce
disulfide bonding of apo E with other sulfhydryl-containing proteins (49).  As a consequence, the
transfer of apo E4 from HDL to chylomicron remnants may be accelerated compared to apo E3,
resulting in an enhanced receptor-mediated clearance of LDL, accumulation of hepatic
cholesterol, down-regulation of LDL-receptors, which leads to elevated concentrations of serum
cholesterol (46).
Apo E polymorphism has usually been ascertained by isoelectric focusing, which may be subjected
in some cases to a significant amount of uncertainty as to the precise phenotype.  One of the
reasons is that the apo E protein contains a considerable amount of carbohydrate, and the
presence of this carbohydrate can alter the isoelectric point (50).  This is especially true in subjects
with diabetes, where the amount of sialic acid on apo E is increased (51).  Moreover, there are
other mutations within the apo E gene that can affect the isoelectric point other than that at the
112 and 158 positions.  More recently, apo E genotyping by PCR has allowed a faster and more
definitive screening for the presence or absence of mutations at residue 112 or 158 (52-54).
Many population studies have investigated the role of apo E phenotype as assessed by IEF in
affecting lipoprotein alterations (41,49,55-69).  These studies have generally shown that the
presence of the apo E4 allele in the heterozygous state is associated with elevations in LDL
cholesterol, while the presence of the apo E2 allele in the heterozygous state is associated with
decreased levels of LDL cholesterol.  It has been estimated in the general population that the apo
E alleles may account for as much as 14% of the normal interindividual variation in plasma total
and LDL cholesterol (49).  However, data from the Framingham Offspring study (60) revealed
that only 1% of the LDL variation was accounted for by the apo E isoforms in male and females
6being pre-menopausal, and 5% in females being post-menopausal.  A meta-analysis has shown
that subjects carrying the apo E2 and E4 alleles are associated with higher triglyceride levels
compared to apo E3/3 homozygotes (58).  Moreover, there have been reports that the presence of
the apo E4 allele is associated with CHD, Alzheimer’s disease, and all-cause dementia (70-75).
Several investigators have recently focused on the interrelationship of lipoprotein responsiveness
to dietary changes and apo E phenotypes (46,76-96), which recently has been reviewed by
Ordovas (97).  While some studies document in individuals having the apo E4 allele a greater
response in plasma lipids (12,79,80,86-90,92,94,98) others failed to note such an effect (76,81-
85,93,96,99-102).  However, a meta-analysis carried out by Ordovas et al. (103) supports the
concept that the apo E4 allele is associated with greater LDL response to changes in dietary
saturated fat and cholesterol.  They also suggest that the responsiveness to diet may be dependent
on age, with genetic variation having a greater impact with increasing age.
Apolipoprotein A-I
Apolipoprotein A-I (apo A-I) is the major protein constituent of plasma HDL and plays a crucial
role in lipid transport and metabolism.  Several epidemiological studies have demonstrated that
HDL-C and apo A-I levels are inversely correlated with the risk of developing coronary heart
disease (104-106).  Some investigators (107,108) believe that the plasma level of apo A-I is a
better discriminator for angiographically assessed coronary heart disease than the level of HDL-C.
In the absence of apo A-I, as in familial apo AI-CIII-AIV deficiency or apo AI-CIII deficiency, a
virtual absence of HDL from plasma is observed, and these patients are at substantially increased
risk for premature atherosclerosis (109-111).  It has been suggested that apo A-I mediates the
reverse cholesterol transport by acting as a ligand for the HDL-receptor (112) and promoting
cholesterol efflux from peripheral tissue back to the liver (113).  Furthermore, it is the major in
vivo activator of the lecithin:cholesterol:acyltransferase (LCAT), an enzyme that catalyzes the
esterification of cholesterol in plasma (114).
Although various environmental factors such as diet, exercise, alcohol, smoking, sex hormones,
and certain drugs can significantly influence the levels of HDL-C and apo A-I (115-118), family
and twin studies demonstrated a strong genetic heritability, accounting for up to 66% of the
variability of HDL-C and apo A-I levels (119,120).
The gene coding for apo A-I is clustered with the genes for apo C-III and apo A-IV on the long
arm of chromosome 11 (121-124).  Several restriction fragment length polymorphisms (RFLPs) in
7the apo AI-CIII-AIV gene cluster have been identified (125-128) and associations with lipid
abnormalities and the risk of CAD have been shown (129,130).
In this study, we investigated the promoter polymorphism located 75 base pairs (bp) upstream
from the apo A-I transcription start site as well as the +83/84 bp mutation located in the first
intron of the apo A-I gene.  While the former mutation at -75 bp is due to a guanine (G) to
adenine (A) substitution (131,132), the latter is created by a cytosine (C) to thymine (T) (+83 bp)
and/or a G to A (+84 bp) interchange which occur either independently or together (133).
With regard to the -75 bp promoter polymorphism, which occurs at a frequency of 0.15 to 0.20 in
Caucasian populations, several controversial results have been published in the literature (see
Table 1).  While some studies (131,134-136) reported in individuals carrying the rare A-allele
higher levels of HDL-C and A-I compared with the G/G wildtype, others (132,137-142)
documented associations only with one of those parameters.  More recent studies (143-148),
however, could not detect an association of the G/A mutation on HDL-C or apo A-I levels at all.
Furthermore, the magnitude and gender distribution of the effects found, differed among studies.
Table 1:  Literature Overview for Apolipoprotein A-I -75 bp Genotype
Author Year Study Subjects Results
Pagani et al. 1990 136 females,
108 males
from Italy
Division of HDL-C into 3 deciles. In women the
frequency of the A-allele increased significantly from
the lowest to the highest decile (0.10, 0.14, 0.27). No
effect in men.
Jeenah et al. 1990 96 males
from England
Males having the A-allele had significantly higher
HDL, HDL2, and apo A-I levels.  Frequency of the A-
allele increased from 0.11 to 0.25 in men with serum
apo A-I concentrations greater than 180mg/dl.
Hayase et al. 1992 162 boys and
young men
from Belgium
Boys and young men having the A-allele had 4.5%
higher apo A-I levels compared to G/G genotype.
Gene-dosage-effect: Increase in A-I levels from G/G<
G/A< A/A.
Sigurdsson et
al.
1992 149 males,
166 females
from Iceland
Significant association between genotype and HDL-C
and apo A-I only in non-smoking men with G/A
having higher levels than G/G. No association was
noted in smokers and females.
Xu et al. 1993 111 boys, 93
girls from
Italy
Boys with the A-allele had significantly higher levels
of total cholesterol (9%), LDL-C (11%), apo B (10%),
and apo A-I (7%) than G/G homozygotes. No
significant effect on any lipid traits was observed in
girls.
 Continued
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Civeira et al. 1993 60 males, 65
females from
Spain
No significant association between the G/A mutation
and levels of HDL-C and apo A-I.
Talmud et al. 1994 825 males,
818 females
from Europe
Females, having the A-allele had significantly higher
apo A-I levels than G/G homozygotes, but no effect
was seen on HDL-C. In males, no significant effect on
apo A-I or HDL-C was observed.
Barre et al. 1994 204 males,
205 females
White
No significant effect of the genotype on HDL-C levels
in either gender.
Saha et al. 1994 148 males,
139 females
from China
Non-smoking men having the A-allele had
significantly higher apo A-I levels (20%) than G/G
homozygotes. No effect in smokers and females.
Furthermore, no effect of the A-allele on HDL-C in
either gender.
Lopez-
Miranda et al.
1994 50 males
from Spain
At baseline, no significant association between the
genotype and lipid traits was observed.
Minnich et al. 1995 345 males,
308 females
from Canada
Females having the A-allele had significantly higher
levels of HDL-C (12%) and apo A-I (10%) than G/G
homozygotes. They suggest no direct effect of A-
allele on HDL-C: 1) no gene dosage effect.  2)
bimodal distribution of HDL-C.  3)
Hyperalphalipoproteinemia only in a subset of
individuals with the A-allele.  In men, no effect of the
A-allele was noted.
Matsunaga et
al.
1995 120 CAD
patients, 125
controls, 199
students from
Japan
Identical frequency of the A-allele between CAD
patients and controls. No effect of the A-allele on
HDL-C, apo A-I, or any other lipid trait in either group.
Students and controls having the G/A genotype had
significantly lower plasma levels of apo A-I.
Akita et al. 1995 168 from
Japan
No significant effect of the genotype on HDL-C levels
regardless of gender or CETP status.
Wang et al. 1996 118 males,
125 females
from
Australia
Adult males and females with the A-allele had higher
HDL-C levels compared to G/G homozygotes. No
effect was observed in children.
Wang et al. 1996 467 males,
177 females
CAD patients
CAD patients with the A-allele did not have higher
levels of HDL-C and apo A-I, but males tended to
have more severe CAD.
Kamboh et al. 1996 252 males,
282 females
US-Whites
Significant raising effect of the A-allele on apo A-I
levels in male non-smokers; no effect in male
smokers or in females. No effect on HDL-C levels in
either gender.
Meng et al. 1997 42 males, 44
females from
Finland
Men having the A-allele had significantly higher levels
of HDL-C and apo A-I than G/G homozygotes. No
effect was observed in females.
 Continued
9Author Year Study Subjects Results
Carmena-
Ramon et al.
1998 25 males, 44
females from
Spain
G/A heterozygote males and females had significantly
lower levels of total cholesterol, LDL-C, and apo B
compared to G/G homozygotes. No effect on HDL-C
levels.
Mata et al. 1998 26 males, 24
females from
Spain
G/A heterozygotes had significantly higher levels of
plasma cholesterol, LDL-C, and triglyceride than
those with the G/G genotype did. No effect on HDL-C.
Larson et al. 1999 373 males,
361 females
from America
Significant raising effect of the A-allele on levels of
apo B, total cholesterol, LDL-C, and TC/HDL-C ratio
in women, but not in men.  No effect on HDL-C levels
in either gender.
With regard to the +83/84 bp polymorphism, only little is known.  The few studies published are
not congruent (see Table 2).  Wang et al. (141) reported in healthy Caucasians carrying the rare
M2- allele significantly higher HDL-C levels compared to homozygotes carrying the common
M2+ allele.  However, investigating CAD patients, Wang et al. (146) failed to observe the
positive effect of the rare +83 bp allele on HDL-C and A-I levels; instead they noted even more
severe coronary artery disease.  The most recent report by Carmena-Ramon et al. (148) on 69
heterozygotes for familial hypercholesterolemia (FH) failed to show an association between the
+83 bp polymorphism and lipids.
Table 2:  Literature Overview for Apolipoprotein A-I +83bp Genotype
Author Year Study Subjects Results
Wang et al. 1995 118 males,
125 females
from Australia
Subjects heterozygous for the rare M2- allele had
significantly higher HDL-C levels compared to the
M2+/+ homozygotes.
Wang et al. 1996 467 males,
177 females
CAD patients
The rare M2- allele was not associated with higher
levels of HDL-C and apo A-I in either gender. In
males, however, the frequency of the rare M2- allele
was significantly higher in patients with more severe
CAD.
Kamboh et al. 1996 252 males,
282 females
US-Whites
Significant raising effect of the rare M2- allele on apo
A-I levels in male non-smokers; no effect in smokers
or in females. No effect on HDL-C levels in either
gender.
 Continued
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Author Year Study Subjects Results
Carmena-
Ramon et al.
1998 25 males, 44
females from
Spain
No association of the rare M2- allele with altered
baseline lipids nor with dietary response was
observed in either gender in heterozygous FH.
Larson et al. 1999 373 males,
361 females
from America
Significant raising effect of the rare M2- allele on
levels of apo A-I and total cholesterol in males, and
lowering effect on levels of total cholesterol in
females. No effect on HDL-C levels in either gender.
Studies on response to a high fat, high cholesterol diet have shown in non-human primates that
the apo A-I gene locus is responsible for up to 33% of the variation (149).  In humans, Xu et al.
(138) found less significant associations (6%) between the apo A-I locus and dietary induced
changes in apo A-I levels.  Lopez-Miranda et al. (144) studied 50 young males carrying the A-
allele and reported greater responsiveness to dietary changes than in subjects being homozygous
for the common G-allele.  After having switched from a low fat to a high fat, high
monounsaturated fat diet (40% fat, 22% MUFA), significant increases in LDL-C were observed
in the G/A group versus the G/G group.  On the other hand, diet modification from a saturated
fatty acid (SFA) to a polyunsaturated fatty acid (POLY) diet resulted in greater total and LDL
cholesterol reduction in G/A subjects as compared to G/G subjects (150).  In contrast, others
(136) documented no significant difference between apo A-I genotypes and lipid traits in response
to a low cholesterol, low fat diet.  With regard to the +83 bp polymorphism, only one study (148)
has been published, documenting no effect of the genetic variation on lipid phenotypes.
Therefore, the purpose of this study was to further elucidate the physiological influence of these
two apo A-I polymorphisms (-75 bp and +83 bp) separately and jointly on various quantitative
traits, in particular on apo A-I levels.  In addition, we wanted to investigate whether or not plasma
LDL-C responsiveness to changes in dietary fat saturation and cholesterol content is partly
explained by the variation at the apo A-I gene locus.
Apolipoprotein A-IV
Human apolipoprotein A-IV (apo A-IV) is a plasma glycoprotein with a molecular mass of 46
kDa, consisting of 376 amino acid residues (151-153).  Apo A-IV is synthesized predominantly in
the enterocytes of the small intestine during fat absorption as prepro apo A-IV.  The mature
protein is secreted into the lymph incorporated onto the surface of nascent chylomicrons
(154,155).  After entry into the bloodstream apo A-IV is found in plasma associated with very
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low density lipoprotein (VLDL) (153,156), HDL (157,158), and in the lipoprotein free fraction
(156,159).  Early reports using ultracentrifugation, indicated that the majority of apo A-IV is
located in the latter fraction, while Lagrost et al. (158) using high performance gel filtration
documented that apo A-IV is primarily associated with the HDL fraction.  The average level of
plasma apo A-IV ranges from 14 to 37 mg/dl according to the immunological method of
determination (156,157,159).
Although its precise function remains unclear, apo A-IV has been proposed to play a role in the
metabolism of triglyceride-rich lipoproteins and HDLs.  In vitro studies have shown that the
activation of lipoprotein lipase by apo C-II can be mediated by apo A-IV (160).  Furthermore,
apo A-IV seems to play an important role in the reverse cholesterol transport as it can serve as an
activator for lecithin:cholesterol:acyltransferase (LCAT), the enzyme responsible for cholesterol
esterification (161,162).  It also has been reported that apo A-IV containing lipoproteins can
promote cholesterol efflux from cultured cells in vitro (163-166), and there is evidence that apo
A-IV may be one of the ligands for the putative HDL-receptor (167) as well as participate in the
HDL particle conversion by cholesterol ester transfer protein (CETP) (168-170).  In transgenic
mice overexpressing mouse apo A-IV, a protective effect was observed against the formation of
diet-induced aortic lesions, which seemed to be due to the influence of apo A-IV on the
metabolism and antiatherogenic properties of HDL (171).  In addition, research on apo A-IV
knockout mice demonstrated that apo A-IV played a role in increasing HDL-C levels by inhibiting
the fractional catabolic rate (FCR) of HDL-cholesteryl ester (172).
The structural gene for apo A-IV is located on human chromosome 11q and is in close linkage
with apo A-I and apo C-III genes (173,174).  Genetically determined polymorphisms of apo A-IV
have been detected in humans (175-177) and in other mammalian species (178,179).  Using
isoelectric focusing and immunoblotting (176), several isoforms of apo A-IV have been detected.
The most common isoform in all population studies is apo A-IV-1 with an allele frequency in
Caucasians ranging from 0.89 to 0.97.  Apo A-IV-2, created by a G to T nucleotide exchange
resulting in an amino acid substitution, where glutamine (Gln) replaces histidine (His) at residue
360, is the second most common isoform.  The allele frequency is in the range of 0.03 to 0.11 in
Caucasians (Table 3).  Other rare isoforms (apo A-IV-0, apo A-IV-3 through apo A-IV-7, apo A-
IV-Tokyo) have been found (176,180-183), which some of them are restricted to a particular
ethnic group.  Additional variation within the apo A-IV gene locus has been detected (184).
Using nucleotide sequencing after polymerase chain reaction (PCR) amplification, Boerwinkle et
al. (184) detected within subjects with the apo A-IV-1 isoform an A to T polymorphism that
results in threonine (Thr) to serine (Ser) substitution at amino acid position 347.  This mutation
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does not alter apo A-IV charge properties and has therefore not been identified by isoelectric
focusing methods.  The frequencies for the rare S-allele were 0.16 - 0.20 and for the more
common T-allele were 0.80 - 0.84.
The impact of apo A-IV genetic variation in determining plasma lipoprotein levels has been
investigated in several population studies (Table 3).  The results, however, are very contradictory.
Some studies observed a significant effect of the apo A-IV 360 polymorphism on HDL-C levels
(185-187), others on triglyceride levels (186,188), or on glucose or insulin levels (189,190).
Concerning apolipoproteins levels, associations between the 360 mutation and levels of apo A-I
(191) and apo A-IV (192,193) have also been described.  Conversely, several investigators failed
to show any effect of the apo A-IV 360 polymorphism on glucose, lipid and lipoprotein
phenotypes (193-196).
Table 3:  Literature Overview of the Effects of Apolipoprotein A-IV 360 Genotype
on Biochemical Parameters
Author Year Females/
Males
PopulationFrequency
of AIV-2
Findings
Menzel 1988 260/
213
Austrian 0.08 Significant association of  A-IV-1/2
phenotype with higher HDL-C levels.
De Knijff 1988 / 1393 Dutch 0.08 No effect of A-IV phenotype on
lipids and on apo A-I levels.
Menzel 1990 93/  95 Icelandic 0.11 Apo A-IV-1/2 phenotype significantly
raised HDL-C levels and lowered
TG levels. No effect on A-IV levels.
Visvikis 1990 158 French 0.06 Significant association of apo A-IV-2
allele with elevated glucose levels,
but no effect of apo A-IV phenotype
on any lipid traits.
Hanis 1991 253/
78
Mexican
American
0.07 No effect of A-IV phenotype on
glucose or lipid levels. Weak
association of  the apo A-IV-2
isoform with apo A-I resulting in
higher levels.
Kamboh 1991 82/
204
Diabetic
Controls,
U.S.
0.08 No effect of apo A-IV phenotype in
diabetics, except in males, A-IV-1/2
heterozygotes had higher fasting
insulin levels. In controls, females
carrying the 2-allele had higher
levels of LDL-C. No difference in A-
IV phenotype distribution between
diabetics and controls.
Continued
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Author Year Females/
Males
PopulationFrequency
of AIV-2
Findings
Kamboh 1992 188/
238
Diabetic
Controls
Hispanic
0.10
0.07
No effect of A-IV phenotype on any
trait in diabetics. In control group,
females with the 2-allele had lower
levels of HDL, HDL2, and HDL3
cholesterol than A-IV-1
homozygotes.
v. Eckardstein 1992 291 German 0.07 A-IV-1/2 heterozygotes had
significantly higher concentrations
of LDL-C and lower Lp (a) levels
compared to A-IV-1/1 homozygotes.
No other effect on lipid traits was
found.
v. Eckardstein 1993 / 275 CAD
patients
0.08 A-IV-1/2 heterozygotes showed 30%
lower Lp (a) concentration than 1/1
homozygotes. Relative frequency of
Lp (a)  concentration >20mg/dl was
significantly increased in 1/1
phenotypes. Other parameters were
not associated with apo A-IV
phenotype.
v. Eckardstein 1994 188/
426
CAD
patients
Germany
0.07 Males with the A-IV-1/2 phenotype
had significantly  higher levels of Lp
A-I and A-IV, higher plasma activity
of LCAT than 1/1 homozygotes. In
both genders, a lower activity of
CETP in apo A-IV-1/2 heterozygotes
was observed. No effect on any
other lipid traits.
Zaiou 1994 105 French No effect of  apo A-IV phenotypes
on any lipid traits.
Ehnholm 1994 1890 EARS-I 0.05 No effect of apo A-IV genotype on
HDL-C, apo A-IV, or any other lipid
traits.
Verges 1994 83/ 100 NIDDM
Controls
No effect of apo A-IV phenotype on
any lipid traits in NIDDM subjects. In
controls, apo A-IV-1/2
heterozygotes were associated with
higher levels of HDL and HDL2
cholesterol.
Carrejo 1995 119 American 0.05 No effect of the apo A-IV genotypes
on lipids, apo A-I, apo C-III, or apo
A-IV levels.
Malle 1996 141/ 99 Turkish 0.03 No significant influence of the A-IV
phenotypes on plasma lipids, apo A-
I, apo B, and apo E was observed in
either gender.
Continued
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Author Year Females/
Males
PopulationFrequency
of AIV-2
Findings
Wang 1997 145 Chinese 0.06 Homozygotes and heterozygotes for
the apo A-IV-2 isoform exhibited a
significantly higher TC
concentrations compared to the apo
A-IV-1/1 homozygotes. No effect on
A-IV levels.
Saha 1997 / 176 Indian 0.03 Marginal effect of the 2-allele on
reduced LDL-C and increased
triglyceride levels compared to 1/1
homozygotes.
Lehtinen 1998 / 71 Saami 0.06 Significantly higher HDL cholesterol
levels in Saami with apo A-IV-1/2
genotype compared to A-IV-1/1
genotype.
/ 177 Finnish 0.11 No significant effect on any lipid
trait.
Fischer 1999 772 EARS II 0.07 Significantly lower BMI values in
control subjects carrying the 2-
allele; a borderline significance was
observed for lower total cholesterol
and triglyceride levels.
Larson 1999 361/
373
American 0.08 No significant effect of the apo A-IV
genotype on lipids, lipoproteins, and
apo A-IV levels. In females,
significant association of apo A-IV-
1/2 heterozygotes with elevated
glucose levels compared to apo A-
IV-1/1 homozygotes.
With regard to the apo A-IV 347 mutation, only very little is known (Table 4).  While one study
documented (197) a significant association of the rare S-allele with lower plasma apo B in both
sexes and with lower LDL-C levels, others (195) did not note an effect on any lipoprotein and
apolipoprotein levels.
With regard to the effect of genetic variation on dietary response, only little is known.  For apo A-
IV 360 mutation, some studies (12,144,150,198) indicated that the presence of the A-IV 2-allele
resulted in reduced responsiveness of LDL-C levels to dietary cholesterol and fat restriction.  In
contrast, another study (199) detected a greater responsiveness of HDL-C and apo A-I levels in
subjects carrying the 2-allele.  Concerning the 347 mutation, differences in LDL-C and apo B
response (200), as well as in triglyceride-rich lipoproteins (201) response to diet modifications
have been documented.
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Table 4:  Literature Overview of the Effects of Apolipoprotein A-IV 347 Genotype
on Biochemical Parameters
Author Year Females/
Males
PopulationFrequency
of AIV-2
Findings
v. Eckardstein 1992 291 German 0.16 The rare S-allele was significantly
associated with lower plasma apo B
concentrations in both sexes, and
with lower LDL-C levels in men.
Tenkanen 1992 NA Finnish 0.18 No effect of the apo A-IV-S allele on
plasma lipid and lipoprotein levels in
hyperlipidemic men and normal
controls.
Carrejo 1995 119 Hyperlipi
demics
0.17 No effects of apo A-IV genotypes on
lipid traits or apo A-I, C-III, or apo
A-IV levels.
Saha 1997 / 176 Indian 0.12 Significant effect of S-allele on lower
non-fasting total and LDL
cholesterol compared to T/T
homozygotes.
Fischer 1999 745 EARS II 0.19 In controls, significant effect of S-
allele on higher values of BMI and
waist/hip ratio as well as higher
levels of total cholesterol,
triglyceride, and apo B.
Larson 1999 361/
373
American 0.20 No effect of apo A-IV genotypes on
lipid, lipoprotein, or apo A-IV levels
in both sexes.
NA = Not Available
Lipoprotein Lipase
Lipoprotein lipase (LPL) is a key enzyme of lipid metabolism and cellular energy balance.  The
primary function of LPL is the hydrolysis of core triglycerides of circulating chylomicrons and
VLDL (202).  In the presence of its cofactor apo C-II, LPL releases monoglycerides and free
fatty acids which are taken up by skeletal muscle or adipose tissue for oxidation or storage
(203,204).  Besides its lipolytic function, LPL is believed to enhance the binding of apo E-
containing lipoproteins to the low density lipoprotein (LDL) receptor-related protein (LRP), and
therefore, plays an important role in the catabolism of chylomicron remnants (205).  In addition,
during lipolysis, surface components such as apolipoproteins and phospholipids, are transferred
from triglyceride-rich lipoproteins to high-density lipoproteins 3 (HDL3) particles to form HDL2
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particles.  This transfer accounts for the positive correlation between post heparin plasma LPL
activity and plasma HDL2 concentration (206).  These HDL2 particles play a crucial part in the
"reverse cholesterol transport" by taking up tissue cholesterol and transporting it to the liver for
excretion.  Several studies have observed an inverse relationship between HDL2 concentrations
and the extent of CHD (5,126,207).  Due to its role in the maturation of HDL and the metabolism
of other lipoproteins, variability of LPL activity may represent a risk factor for CHD (208).  LPL
is synthesized in parenchymal cells of a variety of tissues, including skeletal muscle, adipose,
heart, lung, brain, and macrophages (209).  Its physiological location, however, is on the luminal
surface of the capillary endothelium, where it is anchored to the cell surface through ionic
interaction with membrane-bound glycosaminoglycan chains (210).
The human LPL gene is located on chromosome 8p22 (211) and its gene structure and cDNA has
been described (212-216).  The gene spans approximately 30 kb and the first 9 of 10 exons code
for a protein containing 475 amino acids, including a 27 amino acid signal peptide that is cleaved
posttranslationally to yield the mature LPL with a molecular weight of approximately 60 kDa.
Several restriction fragment length polymorphisms (RFLP) in the LPL gene have been
documented and associated with various lipid traits (217-220).  This study focused on the LPL
Hind III polymorphism in which a replacement of a thymine (T) with a guanine (G) base occurs at
position +495 in intron 8 and abolishes an Hind III restriction enzyme recognition site (221).
Although this polymorphism is located in an intron of the LPL gene, it has been hypothesized that
the more common H+ allele (presence of cutting site) is associated with a lower LPL activity
compared to the rare H- allele (absence of the restriction site).  As such, it has been proposed that
carriers with the H+/+ genotype have higher levels of triglyceride and lower levels of HDL versus
carriers of the H-/- genotype.
Previous studies of these relationships have yielded variable results (Table 5).  While in some
studies the common H+ allele of the LPL Hind III polymorphism has been shown to be
significantly associated with hypertriglyceridemia (222-227), hypercholesterolemia (209), lower
HDL levels (209,228,229), elevated apo C-III (229) and apo B levels (226), and premature
coronary heart disease (CHD) (223,226,228,229), other reports failed to note such effects
(222,230-232).  The inconsistency of those reports may be due to small sample sizes or
heterogeneity with regard to ethnic backgrounds, age, and sex of study subjects.
Regarding response to diet changes, only two studies have been published, indicating different
results.  While one study (233) found a reduced responsiveness of the common H+/+ genotype on
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total cholesterol, the other study (234) reported an increased reduction of VLDL triglyceride and
apo B compared to subjects carrying the rare H- allele.  Therefore, further research is necessary to
elucidate the Hind III genotype effect on lipid response to diet in a large population.
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Table 5:  Literature Overview of the Effects of Lipoprotein Lipase Hind III Genotype on Biochemical Parameters
Author Year Females/
Males
Population No Association Significant
Association
H+
Higher
H+
Lower
M/F P
values
Chamberlain, J.C 1989 98 / Caucasian TC, HDL, TG
Heinzmann, C. 1991 190 US Whites LDL, TG TC * 0.025
Peacock, R.E 1992 93 / Swedish men VLDL-C, VLDL-
TG  HDL
TG * M 0.030
Ahn, Y.I 1993 250 / 281 Normoglycemic Insulin, Glucose TG * M / F <0.001
Non-Hispanic Whites
(NHW)
TC, LDL HDL * M / F 0.005
185 / 196 Hispanics (H)
43 / 32 NIDDM (NHW) Glucose, TC,
LDL,
75 / 116 NIDDM (H) HDL, TG Insulin * M 0.009
Mattu, R.J. 1994 123 / English men TG, HDL, Apo AI TC * M 0.021
Apo B * M 0.005
LDL * M 0.010
Mitchell, RJ. 1994 144/ Mediterranean LDL TG * M 0.030
HDL * M 0.008
Gerdes, C. 1995 446 / Danish men TC, Non-HDL-C,
TG
HDL * M 0.030
Jemaa, R. 1995  74 / 162 French (obese) TC, LDL, Lp AI, VLDL-C * F <0.010
Apo B, Apo AI VLDL-TG * F <0.050
HDL * F <0.050
HDL2 * F <0.050
TG * F <0.050
Continued
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Author Year Females/
Males
Population No Association Significant
Association
H+
Higher
H+
Lower
M/F P
values
Jemaa, R. 1995     725 European (Multicenter) TG Apo CIII * <0.010
HDL * <0.050
Vohl, M-C. 1995   52 / Caucasians TC, LDL, HDL,
HDL2 , HDL3, TC/
HDL, TG
M
Georges, J.L. 1996 193 /
193
French Canadians BMI, TG M / F
Chen, L. 1996 131 /
107
Caucasians TC, HDL, TG M / F
Peacock, R. 1997 101 /
102
Icelandic non-smokers HDL, TG, Apo
CIII, Apo AI
M / F
47 /  58 Icelandic smokers HDL, TG, Apo
CIII, Apo AI
TG * F 0.001
Larson, I. 1999 341 /
342
Americans Fast. Gluc, HDL, TC * F 0.039
TG LDL * F 0.004
HDL * M 0.003
M: Males, F: Females, TC: Total Cholesterol, VLDL: Very low density lipoprotein, LDL: Low density lipoprotein, HDL: High-density lipoprotein, TG: Triglyceride, Fast. Insulin: Fasting Insulin, Fast. Gluc:
Fasting Glucose, Apo: Apolipoprotein
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Purpose and Hypothesis
The purpose of this study was to assess the impact of genetic variants at the APOE, APOAI,
APOAIV, and LPL gene loci in determining serum glucose, lipids, lipoproteins, and plasma
apolipoproteins at baseline as well as in response to diet and behavioral modifications.
The aim of the study was to provide more definitive information about the interaction of genetic
variants with plasma lipids (specifically low-density lipoprotein cholesterol) in order to more
accurately assess potential responsiveness of individuals to dietary modification.
The hypotheses tested included:
1. Common genetic variants at the APOE gene locus are significant determinants of LDL
cholesterol and apoE levels, and LDL-C lowering in response to diet.
2. The -75 bp and +83 bp polymorphisms at the APOAI gene loci are significantly associated
with plasma levels of apo A-I and HDL-C, as well as LDL-C lowering in response to diet.
3. The 360 and 347 polymorphisms at the APOAIV gene loci significantly influence levels of
apo A-IV, HDL-C, and triglyceride, and LDL-C lowering in response to diet.
4. The common Hind III polymorphism at the LPL gene locus has a significant impact on
triglyceride and HDL-C levels, as well as LDL-C reduction in response to diet.
5. Plasma lipid levels in women are less responsive to lifestyle intervention than in men.
6. Intensive lifestyle intervention with diet and exercise has a significant effect on serum lipid
response short-term, but only little effect long-term.
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Materials and Methods
Subjects and Lifestyle Intervention
A total of 734 middle-aged and elderly subjects participated in this study.  All 361 females and
373 males took part in a lifestyle modification program at the Pritikin Longevity Center in
California.  The majority of the patients entered the program to reduce their risk for heart disease
as well as to reduce their body weight.  All participants signed a consent form, permitting use of
their data for research purposes.  Data were obtained from the medical records kept on each
patient.
Subjects checked into the center on a Sunday afternoon, and following the evening meal attended
an orientation where they received information about the program and instructions for a 12-hour
fast.  On Monday morning, fasting blood was drawn between 6:30 and 7:30 AM while subjects
were in a seated position.  A second set of blood was drawn from all subjects on the following
Monday, while on a subset of 31 participants, a third blood sample was taken after 15 days.
Subjects were seen by a physician who conducted an initial medical history and physical
examination, and who then sent them for a multi-stage symptom-limited treadmill test.
Immediately following this test, the results were analyzed by a physician, who assigned a training
heart rate for their exercise program.  Furthermore, participants met with an exercise physiologist
who wrote an exercise prescription for daily walking.  The prescription initially called for 30-40
minutes (min) of walking, six days per week, and every other day subjects were to walk fast
enough to get their heart rate just below the training heart rate.  At the end of each week a new
prescription was given to each subject to increase the duration and intensity of their daily walking.
In addition to daily walking, the subjects also attended an organized exercise class that met for 60
min, five days per week, and consisted of stretching and flexibility activities, some muscle
conditioning, and aerobic exercise on a treadmill or bicycle ergometer.
During their stay at the center, the subjects were provided with meals, which were high in
complex carbohydrate and fiber, and low in total fat, cholesterol, and salt.  Less than 10% of total
calories were derived from fat and the ratio of polyunsaturated to saturated fat (P/S) was
estimated to be 2.4.  Fifteen percent of the calories were derived from protein, and the remainder
from carbohydrate, of which 90% was unrefined.  The diet provided 35-40 grams of dietary fiber
per 420 kJ, and a total daily intake of 1.6 grams or less of sodium chloride.  Cholesterol was
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limited to 25 mg per day (or 0.06 mmol/day), while the subjects were at the center, and they were
encouraged to limit cholesterol intake to <100 mg per day  (or 0.26 mmol/day), once they left the
program.  The diet consisted primarily of whole grains, cereals, beans, peas, other vegetables, and
fresh fruit.  Protein was derived primarily from vegetable sources and, except for nonfat milk,
limited amounts of nonfat cheese, fish, or poultry.  The food served at the center was all natural
food, most of which are readily available in the standard market.
Details concerning the diet have been previously published (13).  Those individuals wishing to
lose weight were instructed on how to restrict calories, while ensuring an adequate intake of
required nutrients.  Female subjects were instructed not to reduce caloric intake to <420 kJ per
day, and male subjects to no less than 504 kJ per day.  Rapid weight loss was discouraged.  All
subjects attended educational classes and lectures that can be divided into three different groups.
The first group of classes dealt with the major diseases (hypertension, diabetes, cancer, and
coronary heart disease) and the roles that diet and exercise play in their management and
prevention.  A second group of lectures dealt with various aspects of nutrition, and were
conducted with cooking classes, while a third group of lectures dealt with lifestyle management,
including understanding and coping with stress.  Special smoking cessation classes were offered.
As mentioned before, a subset of 31 individuals (9 females and 22 males) who participated in the
three-week program was independently analyzed.  The reason was to ascertain what the effects on
lipid response would have been, had the subjects been sampled at the two-week point.  Therefore,
blood samples were drawn at baseline, eight days, and at 15 days of the intervention.
In addition, to evaluate the long-term effect of this lifestyle modification program on plasma
glucose and lipid traits, another subset of 202 participants was analyzed.  These 95 women and
107 men were seen on two occasions at the Pritikin Longevity Center.  They participated twice in
the same program for two weeks with data analyzed after 8 days of intervention, respectively.
The mean time span between visits was 1.7 years.
Blood Sampling
Fasting blood samples were drawn at admission to the Pritikin Longevity Center.  One set of
samples were placed into two 10-cc EDTA tubes (0.1% EDTA) for the isolation of DNA.  The
second set of samples was placed into two 10-ml tubes containing SST clot activating gel
(Becton-Dickinson vaccutainer system).  These serum sample tubes were allowed to clot and the
serum was separated by high-speed centrifugation for 15 min.  Serum was used for the
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determination of serum lipids and glucose.  Non-HDL lipoproteins were precipitated using the
sodium phosphotungstic acid reagent.  Total cholesterol, HDL-C, triglyceride, and glucose levels
were measured using standard automated enzymatic procedures on an Olympus Autoanalyzer
(Smith-Kline Beecham Laboratories).  LDL cholesterol was calculated by subtracting the sum of
HDL-C and triglyceride divided by 5, from total cholesterol, as described by Friedewald et al.
(235), provided triglyceride values were <400 mg/dl.
Plasma apo E was determined by enzyme linked immunosorbent assay (ELISA), using a
commercially available assay obtained from the Perimmune Corporation (Rockville, MD) (236).
In brief, purified monoclonal antibody bound the apo E and apo E containing lipoproteins to the
ELISA plate well.  Diluted plasma samples (1:400), calibrators, and controls were incubated on
microtiter wells for one hour at 37°C. Unbound plasma components were washed off the wells.
The immune complex was enlarged after an incubation with a polyclonal anti-apo E horseradish
peroxidase (HRP) conjugate for one hour at 37°C.  The wells were washed and a chromogenic
substrate (tetramethyl-benzidine (TMB)) with hydrogen peroxide was added for 30 min at room
temperature.  This allowed the HRP enzyme, specifically bound through the immune complex, to
react with the TMB to form a blue colored solution.  Addition of stop solution turned the solution
yellow.  The absorbance of each well was determined at a wavelength of 450 nm and was
proportional to the concentration of apo E in the sample.  The calculated within and between run
coefficients of variation (CVs) were less than 10%, respectively.
Plasma apo A-I and apo B were determined with a Spectrum CCX analyzer (Abbot Diagnostics)
using commercially available standardized immunoturbidimetric assays from Incstar Corporation
(Stillwater, MN).  The methods are described in detail by Contois et al. (237,238).  In brief, 20 ml
of plasma were diluted with 200 ml of sample diluent.  The antiserum preparation was also
prediluted 20-fold with antibody diluent.  The analyzer transferred either 3 ml (for apo A-I) or
12.5 ml (for apo B) of diluted plasma to the cuvette, along with 265 ml eac of diluted antiserum.
The reactions were monitored at 340 nm and 37°C.  Serum blanking was used to account for
potential interference by sample turbidity.  The calculated within and between run coefficient
variations (CVs) were less than 2% and 5%, respectively for apo A-I and less than 3% and 11%,
respectively for apo B.
Plasma apo A-IV levels were measured by electroimmunodiffusion technique using the Hydragel
apo A-IV kit obtained from Sebia (Sebia, Issy-les Moulineaux, France) as previously described
(239).  This kit provided agarose gels with incorporated anti apo A-IV monospecific antibodies.
Fife mL of saline diluted standards and pure samples were applied into the wells of the gel.
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Dispersion of all samples prior to migration for 20 min was allowed in order to obtain a
homogenous diffusion.  Placement of the gel into the electrophoresis chamber and migration at 40
V, 15 mA for 10 min, followed by 130 V, 15 mA for 110 min.  Subsequently, the remaining
proteins were absorbed by applying filter paper previously soaked with saline under pressure of 1
kg for 20 min.  This procedure was repeated of for another 10 min after having washed the gel
with saline.  The gel was dried at 80°C, immersed in a staining solution, destained, and dried
again.  The immunoprecipitated rockets were measured and their heights were proportional to
apo A-IV concentrations.  The calibration was performed using standard sera calibrated to
apolipoprotein AIV.  The calculated within and between run coefficient variations (CVs) were
less than 8%, respectively.
All assays were run on frozen plasma, stored at -80°C, and thawed only once.  No significant
differences in fresh versus frozen plasma values for apo E, A-I, A-IV, and apo B were noted.
DNA Isolation
The genomic DNA was isolated from 200 l EDTA blood using the QIAamp Blood Kit (Qiagen
GmbH, Germany).  The procedure was comprised of three steps.  The first step included lysis of
the blood, which was initiated by the addition of the enzyme proteinase K and lysis buffer
provided by the manufacturer.  The sample was incubated at 70°C for 10 min, and ethanol (99%)
was added to stop cell lysis.  The second step included placement of the mixture onto a spin
column.  The subsequent washing and centrifugation procedures ensured the proper purification
of the DNA.  While the DNA was bound to the spin column filter, the rest was discarded in the
filtrate.  The last step included the elution of the DNA with distilled water.  To increase the yield
of the DNA, water was preheated at 70°C.
DNA Concentration and Purity
The DNA concentration and purity were measured with a Photospectrometer DU-600 (Beckman
Instruments GmbH, Germany).  After diluting the DNA samples with distilled water (1:50),
extinction was measured at the wavelength of 260 nm (maximum of absorption for nucleic acids)
and 280 nm (maximum of absorption for proteins).  Regarding the DNA concentration, 1 OD260
was equivalent to either 50 mg/ml dsDNA or 20 mg/ml oligonucleotides.  The average DNA
concentration of the samples used was 30 ng/ml.
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With regard to the purity of the DNA, the relation of OD260 /OD280 resembles the grade of protein
pollution of a nucleic acid solution.  The recommended range of 1.7 to 1.9 in a protein free
solution was kept.
Genotyping
The genotyping was performed using the polymerase chain reaction (PCR) followed by the
determination of restriction fragment length polymorphisms (RFLPs).
Polymerase Chain Reaction (PCR)
The polymerase chain reaction is a highly specific, reliable and fast method to amplify specific
DNA segments.  The idea behind it is to copy in vitro the identical reduplication of a single-
stranded DNA sequence (see Figure 2).  The procedure includes three steps.  The first step
includes heat denaturation that mimics the naturally occurring enzymatic separation of double-
stranded DNA into two single strands.  In the second step, two oligonucleotide primers frame the
selected DNA segment.  Each primer is complementary to the flanking sequence of one of the
original single strands.  They hybridize with their 3´-OH ends to the DNA in a way that the
amplification only occurs in the direction of the target sequence.  The last step incorporates the
extension of the primers with the help of the thermostable "Thermus aquaticus" (Taq) DNA
polymerase.  Repetition of these cycles (denaturation, primer annealing, and extension) result in
an exponential amplification (2n) where (n) resembles the number of cycles.
Restriction Fragment Length Polymorphism (RFLP)
The RFLP-method is used in this study to identify different isoforms of a specific polymorphism.
The principal behind it is to find a restriction enzyme that creates or omits a cutting site at the
location of the gene mutation.  Therefore, it is required to know the gene sequence, location and
type of mutation to select the proper restriction endonuclease.  It also should be taken into
consideration that the enzyme does not cut too often within that sequence, as fragments under 30
bp are difficult to identify.  The HUSAR-system was used for optimal enzyme selection.
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Figure 2:  Mechanism of the Polymerase Chain Reaction (PCR)
Apolipoprotein E Genotyping
The amplification of the 244 base pair (bp) fragment located in the exon 4 of the apo E gene was
done by the polymerase chain reaction (PCR).  Primers used were (52):
F6: 5´-taagcttGGCACGGCTGTCCAAGGA-3´ (sense)
F4: 5´-acagaattcGCCCCGGCCTGGTACAC-3´ (antisense)
 Polymerase Chain Reaction 
Double Stranded DNA
Denaturation & Primer
Annealing
Chain Elongation
Denaturation &
Annealing
 Cycle of Synthesis &
Amplification
After 4-25 Cycles DNA Fragment Has Been Amplified 105 Times
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The amplification reaction of 50 ml contained 3 mg genomic DNA, 1x PCR buffer (20 mM Tris-
HCl, pH 8.4, 50 mM KCl), 2.5 mM MgCl2, 0.3 mM each of dATP, dCTP, dGTP, and dTTP, 0.6
mM of each primer, 10% dimethylsulfoxide (DMSO), and 1.5 U of Taq DNA polymerase (Gibco,
BRL).  The mixture was overlaid with mineral oil and placed into an UNO-Thermoblock Cycler
(Biometra, Germany).  Amplification protocol consisted of an initial denaturation step at 95°C of
5 min, following 32 cycles of denaturation at 94°C for 1 min, primer annealing at 60oC, and
extension at 72°C for 2 min, and a final extension at 72°C for 5 min.  Sixteen microliters of the
PCR product were digested with 2 ml of restriction endonuclease Cfo I (10 U/ml) and 2 ml of the
buffer provided by the manufacturer (Boehringer Mannheim, Germany) at 37°C for 3 hours.  The
digested DNA fragments were loaded onto a 4% NuSieve/agarose gel (1:3) stained with ethidium
bromide and electrophoresed in 1x TBE buffer (89 mM Tris-borate, 2 mM EDTA, pH 8.3) for 45
min at 100 V.  The DNA bands were visualized by UV-light at a wavelength of 322 nm.  Pictures
were taken with Polaroid film.  The marker V (Boehringer Mannheim, Germany) served as a
control standard.  Figure 3 shows the various apo E genotypes on a polyacrylamide gel, which
allowed a higher resolution of the small fragments.
Figure 3:  DNA Fragments of Apo E Genotype after PCR and RFLP
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The resulting RFLP fragments are shown in Figure 4.
Figure 4:  Apo E Genotyping
Apolipoprotein A-I Genotyping
The 435 bp apo A-I gene fragment, including the -75 bp polymorphism in the promoter region
and the +83/84 bp mutations located in the first intron, was amplified by PCR, followed by
simultaneous digestion with the restriction endonuclease MspI.  The oligonucleotide pair used
was described by Saiki et al. (240):
P1: 5´-AGGGACAGAGCTGATCCTTGAACTCTTAAG-3´ (sense)
P2: 5´-TTAGGGGACACCTACCCGTCAGGAAGAGCA-3´ (antisense)
The 50 ml amplification mixture contained 60 ng genomic DNA, 50 mM KCl, 20 mM Tris-HCl,
(pH 8.4), 2.5 mM MgCl2, 0.6 mM of each primer, 0.2 mM each dNTP, 10% DMSO, and 1.5
Units of Taq DNA polymerase (Gibco, BRL).  The amplification protocol was executed by an
UNO-Thermoblock Cycler (Biometra, Germany) and consisted of an initial denaturation step at
95°C for 3 min, followed by 30 cycles of primer annealing and extension at 94°C for 30 sec, 60°C
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for 45 sec, and 72°C for 1 min, and ended with a final extension at 72°C for 5 min.  The PCR
product was digested with 2.5 units of MspI (Boehringer Mannheim, Germany) for 3 hours at
37°C.  The digested DNA fragments were loaded onto a 4% NuSieve/agarose gel (1:3) (FMC,
BioProducts) with incorporated ethidium bromide and subjected to electrophoresis for 45 min at
100 V.  The bands were visualized by an UV-transilluminator.  The marker V (Boehringer
Mannheim, Germany) served as a control standard (Figure 5).
Figure 5:  DNA Fragments of Apo A-I –75, +83 bp Genotype after PCR
and RFLP
Concerning the promoter polymorphisms at position -75 bp, the presence of the restriction site,
representing the more common G-allele, resulted in the fragments 209 bp, 114 bp, 66 bp, and 46
bp.  The absence of the restriction site, caused by the G to A substitution, resulted in the
fragments 209 bp, 180 bp, and 46 bp.  With regard to the polymorphism in the first intron of the
A-I gene, the C to T and/or G to A substitutions at positions +83/84 bp abolished the MspI
cutting site and resulted a longer 255 bp DNA fragment in individuals having the rare M2- allele.
The alleles of the -75 bp and 83 bp genotypes as well as the haplotypes are demonstrated in
Figure 6.
APO A-I Genotypes
255
 +/+   +/+  +/+    +/-     +/-    -/-
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Figure 6:  Haplotypes of the Apo A-I –75 bp and +83 bp
Polymorphisms
Apo A-I Haplotypes
-75 +83
-75bp     +83bp
  ß          ß
G M2+ 66 114 46 209
A M2+  180  46 209
G M2- 66 114  255
A M2-  180  255
DNA fragments of the apo A-I -75bp and +83bp haplotypes after amplification and digestion
with the restriction enzyme MspI.
Apolipoprotein A-IV Genotyping
The two different polymorphisms at site 360 bp and 347 bp in the apo A-IV gene were amplified
using PCR procedure.  Primers used were (241):
F1: 5´-CCTGAGGCACAAGGTCAACTC-3´(sense)
R1: 5´-CACCTGCTCCTGCTA*  CTGCTCC-3´ (antisense)
* In the tailored primer (R1), an A is inserted instead of a G that would be the nucleotide
corresponding to the sequence apo A-IV.  This leads to the disappearance of the two Fnu4H1
restriction sites present downstream from the point mutation (see Figure 7, cited from Tenkanen
et al. (241)).
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Figure 7:  A-IV Primer Selection
The 50 ml reaction mixture contained 270 ng genomic DNA, 1x PCR-buffer (50 mM KCl, 20 mM
Tris-HCl, pH 8.4), 1.5 mM MgCl2, 0.5 mM each primer, 0.2 mM each of dATP, dCTP, dGTP,
and dTTP, 15 mM (NH4)SO4, 0.1% tween 20, 0.1 mg/ml gelatin, and 1.5 U Taq DNA
polymerase (Gibco, BRL).  The mixture was overlaid with mineral oil and placed into an UNO-
Thermoblock Cycler (Biometra, Germany) for amplification.  The protocol was as followed:
initial denaturation at 95°C for 3 min, then 30 cycles of 95°C for 1 min, 60°C for 1 min, and 72°C
for 1 min, and a final extension at 72°C for 5 min.  The amplified PCR product was divided into
two tubes for digestion.  To identify the apo A-IV 360 mutation, 25 ml of PCR product were
combined with 0.16 units restriction enzyme Ita I (10 U/ml) (Boehringer Mannheim, Germany).
For the apo A-IV 347 mutation, the other 25 ml were mixed with 1 unit of the restriction enzyme
Hinf I (10 U/ml) (Boehringer Mannheim, Germany).  Both tubes were incubated for 4 hours at
37°C.  The digested DNA fragments were each loaded onto a 4% NuSieve/agarose gel (1:3),
stained with ethidium bromide and electrophoresed for 45 min at 100 V.  The DNA bands were
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visualized by UV-light.  The marker V (Boehringer Mannheim, Germany) served as a control
standard (see Figure 8).
Figure 8:  DNA Fragments of APO A-IV 360,347 Genotypes after PCR
and RFLP
The digestion of the apo A-IV 360 mutation results either in a 127 bp fragment (uncut), which
indicates the presence of the more common apo A-IV-1 allele (Gln), or in two 101 bp and 26 bp
fragments (cut), which indicates the presence of the apo A-IV-2 allele (His).  With regard to the
apo A-IV 347 mutation, the two fragments 64 bp and 63 bp (cut) are due to the presence of the
more common T-allele, while the127 bp fragment (uncut) is due to the less common S-allele
(Figure 9).
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Figure 9:  Apo A-IV 360 and 347 Genotype RFLP Fragments
Apo A-IV 360
Common 1-Allele
101 bp 26 bp
 Rare 2-Allele
127 bp
Apo A-IV 347
Common T-Allele
64 bp 63 bp
Rare S-Allele
127 bp
Lipoprotein Lipase Genotyping
The Hind III genotype in intron 8 of the LPL gene was determined by PCR followed by digestion
with the restriction endonuclease Hind III.  The following oligonucleotides were used for
amplification of the 356 bp product (226):
5´-GATGCTACCTGGATAATCAAAG-3´ (sense)
5´-CTTCAGCTAGACATTGCTAGTGT-3´ (antisense)
The 25ml reaction mixture contained 50 ng genomic DNA, 1x PCR buffer (Gibco, BRL), 0.1 mM
each of dATP, dCTP, dGTP, and dTTP, 0.5 mM of each primer and 0.6 U of Taq DNA
polymerase (Gibco, BRL).  Amplification was performed in an UNO-Thermoblock Cycler
(Biometra, Germany) and consisted of an initial denaturation step at 95°C for 3 min, followed by
35 cycles at 95°C for 30 sec and 57°C for 30 sec, and finished with a final extension at 72°C for 5
min.  The amplified product was incubated with 5 U of Hind III (10 U/ml) (Gibco, BRL)
overnight at 37°C.  The digested DNA fragments were loaded onto a 5% NuSieve/agarose gel
(1:3) (FMC BioProducts), electrophoresed, and visualized by UV-light (Figure 10).  The marker
V (Boehringer Mannheim, Germany) served as a control standard.
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Figure 10:  DNA Fragments of LPL Hind III Genotype
after PCR and RFLP
The resulting RFLP fragments were 356 bp (uncut) for the H- allele, or 217 bp and 139 bp (cut)
for the H+ allele (Figure 11).
Figure 11:  Lipoprotein Lipase Hind III Genotype RFLP Fragments
 Common H+ Allele
217 bp 139 bp
 Rare H- Allele
356 bp
Statistical Analysis
Statistical analysis was performed with the software package SPSS/PC+.  The statistical
significance was set at a=0.05.  Allele frequencies for the various polymorphic sites were
356 bp
217
bp
139
bp
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estimated by gene counting.  Agreement of the genotype frequencies with the Hardy-Weinberg
equilibrium expectations was tested using a C2 goodness-of-fit test.  Linkage disequilibrium
between the apo A-I -75 bp and +83 bp single nucleotide polymorphisms (SNP´s) was also
assessed using the Chi square test.  Regarding apo E genotype, subjects were grouped into E2+
(E2/2, E2/3), E3/3, and E4+ (E3/4, E4/4).  Subjects carrying E2/4 were excluded from the
analysis.  For the apo A-I -75 bp baseline analyses, subjects carrying the A-allele (G/A and A/A)
were combined to increase the power.  With regard to the apo A-I +83 bp genotype, the one
female carrying the M2-/- genotype was excluded from the analysis due to her unusual lipid
profile.  The same was true for the one female carrying the rare apo A-IV 360 2/2 genotype.  She
also was excluded from the analyses.
Distributions of all variables were tested for normality.  Data for body mass index (BMI)
(computed as weight in kilograms divided by height in meters squared), plasma glucose, HDL-C,
and triglyceride were log10 transformed prior to analysis of covariance (ANCOVA) to reduce
skewness of the data.  Antilogs and unadjusted mean values ± standard deviations (SD) of the
lipid traits are presented in all the various tables and figures.  Analyses were carried out separately
for each polymorphism, as well as for females and males, respectively.  Comparisons of all the
biochemical parameters between females and males were performed with Student’s t-test.
Because environmental aspects can influence plasma glucose, lipid, lipoprotein, and
apolipoprotein concentrations, adjustments were made for age in females and age2 in males, BMI,
smoking status, alcohol use, and medications (cholesterol lowering drugs, diabetes medication,
hormonal replacements, and thyroid supplementation).  ANCOVA was performed to test the null
hypothesis that phenotypic variations in these traits were not associated with genetic variation at
the candidate gene loci.  The continuous variables age and BMI were entered in the general linear
model (GLM) as covariates.  The dichotomous variables: smoking status, alcohol use,
medications, and apo E alleles were included as factors.  Apo E alleles (2+, 3/3, 4+) were
incorporated in the analyses of apo A-I, apo A-IV, and Hind III, due to their known effects on
various lipid traits.  In addition, two-way interactions between these factors and the various
genotypes have been added to the model.  In case of significant effects of genetic variability on
lipid traits, one-way ANOVA (Tukey test) or Student’s t-test was performed to compare
interindividual differences between genotypes.
For the analyses of responsiveness, ANOVA-repeated measurements was performed to test the
null hypothesis that differences in fasting glucose, lipid, and lipoprotein response were not
associated with genetic variation at the various candidate gene loci.
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Results
A. Effects of Apolipoprotein E, A-I, A-IV and Lipoprotein Lipase
Genotypes on Baseline Levels of Glucose, Lipid, Lipoprotein, and
Apolipoproteins
Subjects
Data on the 361 females and 373 males are presented in Table 6.
Table 6:  Study Subjects*
Females
(n = 361)
Males
(n = 373)
Percentage
Difference
Age (years) 56.1 ± 13.4 58.7 ± 12.3 † + 4.6%
Body mass index (kg/m2) 28.5 ± 6.8 30.6 ± 5.5 † + 7.4%
Height (cm) 163.9 ± 6.5 177.8 ± 6.6 † + 8.5%
Weight (kg) 76.8 ± 20.5 96.3 ± 19.1 † + 25.4%
Waist (cm) 99.1 ± 17.9 108.8 ± 14.6 † + 9.7%
Cholesterol-lowering medication 42 (5.7%) 77 (10.5%) † + 84.2%
Medication for diabetes 21 (2.9%) 53 (7.2%) † + 148.3%
Hormonal replacement 133 (18.1%) 1 (0.1%) † ! 99.9%
Thyroid medication 87 (11.9%) 22 (3.0%) † ! 74.8%
Alcohol users (>1 drink/week) 144 (40.0%) 195 (52.1%) † + 30.3%
Cigarette smoking (current) 25 (6.9%) 49 (13.1%) † + 89.9%
* Mean values ± SD or number of subjects with percentage of total in parentheses.
† Significantly different (p < 0.05) from females.
The mean age in females was 56.1 years (ranging from 16 to 81 years) and in males 58.7 years
(ranging from 15 to 91 years).  As a group, their body mass index was somewhat elevated, with a
mean of 28.5 kg/m2 in the females and 30.6 kg/m2 in the males.  Men had significantly higher body
weight at 96.3 kg compared to women at 76.8 kg.  With regard to medications, 5.7% of the
females and 10.5% of the males were on cholesterol-lowering medication, 2.9% of the females
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and 7.2% of the males were on medication for diabetes, 18.1% of the females and 0.1% of the
males were receiving hormonal replacement, and 11.9% of the females and 3.0% of the males
were taking thyroid supplementation.  Menopausal status in females was not assessed.  Alcohol
use with more than one drink per week was noted in 40.0% of the females and 52.1% of the
males, and current cigarette smoking was noted in 6.9% of the females and 13.1% of the males.
Significant differences in all of these parameters were noted when males were compared with
females.
Data on biochemical parameters are provided in Table 7.  Males had significantly (p<0.05) higher
values for apo E (7.8%), apo A-IV (6.9%), apo B (6.0%), glucose (12.0%) and the TC/HDL
cholesterol ratio (26.7%) than did females.  They also had significantly lower levels of apo A-I
(10.1%), total (3.2%) and HDL cholesterol (23.6%) than females.  In addition, triglyceride values
were also 21.8% higher in men than in women.  With regard to LDL cholesterol, no significant
gender difference was noted.
Table 7:  Biochemical Parameters*
Females
(n = 361)
Males
(n = 373)
Percentage
Difference
Apo A-I (146.7 ± 21.6) (131.9 ± 17.4) † ! 10.1%
Apo A-IV (14.4 ± 4.2) (15.4 ± 4.9) † + 6.9%
Apo E (10.7 ± 6.8) (11.5 ± 4.57) † + 7.8%
Apo B (109.3 ± 29.8) (115.8 ± 31.6) † + 6.0%
Total Cholesterol 5.56 ± 1.08
(214.6 ± 41.5)
5.38 ± 1.13 †
(207.8 ± 43.8)
! 3.2%
LDL-C 3.15 ± 0.91
(121.5 ± 35.4)
3.21 ± 0.92
(123.8 ± 35.5)
+ 1.9%
HDL-C 1.61 ± 0.39
(62.1 ± 15.2)
1.23 ± 0.32 †
(47.4 ± 12.2)
! 23.6%
Triglyceride 1.74 ± 0.90
(154.0 ± 80.0)
2.12 ± 1.25 †
(187.2 ± 110.2)
+ 21.8%
TC/HDL ratio 3.63 ± 1.0 4.60 ± 1.30 † + 26.7%
Glucose 5.23 ± 2.74
(95.8 ± 39.1)
5.86 ± 2.45 †
(107.3 ± 45.6)
+ 12.0%
* Mean values ± SD, all values, except ratios, are in mmol/L, values in parentheses are in mg/dl, conversions from
mg/dl were division by 18.3 for glucose, 38.6 for cholesterol, and 88.5 for triglyceride.
† Significantly different (p < 0.05) than females.
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Genotype Frequencies
The genotype distribution and allele frequencies of the apo E polymorphism are presented in
Table 8.  The frequencies were similar in men and women, with about 60% of the population
having the apo E3/3 genotype, and about 20% of the population having the apo E3/4 genotype,
and another approximately 12% having the apo E2/3 genotype.  The remainder was divided
among the rarer apo E4/4, apo E2/4, and apo E2/2 genotypes.  The allele frequency for apo E3
was 0.78 in both females and males, for E4 it was 0.16 in females and 0.12 in males, and for apo
E2 it was 0.06 in females and 0.10 in males.
Table 8:  Apo E Genotype Distributions and Allele Frequencies*
Females
(n = 361)
Males
(n = 373)
E 3/3 215 (59.6%) 234 (62.7%)
E 3/4 89 (24.7%) 67 (18.0%)
E 2/3 42 (11.6%) 50 (13.4%)
E 4/4 9 (2.5%) 6 (1.6%)
E 2/4 6 (1.7%) 13 (3.5%)
E 2/2 0 (0.0%) 3 (0.8%)
* Apo E allele frequencies: in females, ,3: 0.78, 4: 0.16, 2: 0.06; in males, ,3: 0.78, 4: 0.12, 2: 0.10.
Genotype distributions and allele frequencies of the apo A-I -75 bp and the +83 bp
polymorphisms, as well as their haplotypes, are presented in Table 9.  With regard to the -75 bp
polymorphism in the promoter region, 74.0% of the women and 70.5% of the men were
homozygous for the common G-allele, 24.4% of the women and 25.7% of the men were
heterozygous, and 1.7% of the women, and 3.8% of the men were homozygous for the rare A-
allele.  Overall, the frequency for the G-allele was 0.86 in women and 0.83 in men, and for the A-
allele it was 0.14 and 0.17 in women and men, respectively. Due to the small sample size of the
latter group, G/A and A/A genotypes were combined and compared with the G/G homozygotes.
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Table 9:  Apolipoprotein A-I -75 bp and +83 bp Genotype Distributions and Allele
Frequencies*
Genotype Females Males
A-I -75 bp
G/G 267 (74.0%) 263  (70.5%)
G/A 88 (24.4%) 96 (25.7%)
A/A 6  (1.7%) 14 (3.8%)
A-I +83 bp
M2+/+ 331 (91.7%) 336 (90.1%)
M2+/- 29 (8.0%) 37 (9.9%)
M2-/- 1 (0.3%) 0 (0.0%)
Haplotypes
G/G M2+/+ 244 (67.6%) 231 (61.9%)
G/A M2+/+ 87 (24.1%) 105 (28.2%)
G/G M2+/- 23 (6.4%) 32 (8.6%)
G/A M2+/- 7 (1.9%) 5 (1.3%)
* Allele frequencies for G and A in females were 0.86 and 0.14, and in males, they were 0.83 and 0.17,
respectively.  Allele frequencies for M2+ and M2- were 0.96 and 0.04 in females and 0.95 and 0.05 in males,
respectively.
Concerning the +83 bp polymorphic site in the first intron of the apo A-I gene, 91.7% of the
women and 90.1% of the men were homozygous for the common M2+ allele, while 8.0% and
9.9% were heterozygous, respectively.  Only one female was homozygous for the rare M2- allele,
and she was excluded from the analysis due to her unusual lipid profile: glucose: 4.75 mmol/L (87
mg/dl), apo A-I: 151.0 mg/dl, apo B: 71.0 mg/dl, total cholesterol: 4.09 mmol/L (158 mg/dl),
LDL-C: 1.66 mmol/L (64 mg/dl), HDL-C: 1.94 mmol/L (75 mg/dl), and triglyceride: 1.05
mmol/L (93 mg/dl).
Linkage disequilibrium (X2: 4.359, p=0.037) was detected between the apo A-I -75 bp and +83
bp polymorphisms.  With regard to the haplotype distribution, 67.6% of the women and 61.9% of
the men had the combination G/G M2+/+, 24.1% and 28.2% of women and men carried G/A
M2+/+, 6.4% and 8.6% had G/G M2+/- and 1.9% and 1.3% of women and men carried both rare
alleles G/A M2+/-, respectively.
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Genotype distributions for the apo A-IV 360 and 347 mutations are shown in Table 10.  With
regard to the 360 (Gln/His) polymorphism, 83.7% of the women and 86.6% of the men were
homozygous for the common apo A-IV-1 allele, 16.1% of the women and 13.4% of the men were
heterozygous (A-IV 1/2).  Only one female was homozygous for the rare A-IV-2 allele.  Her lipid
profile was: fasting glucose 4.64 mmol/L (85.0 mg/dl), apo A-I: 109.0 mg/dl, apo A-IV: 11.4
mg/dl, apo B: 59.0 mg/dl, total cholesterol: 3.24 mmol/L (125.0 mg/dl), LDL-C: 1.81 mmol/L
(70.0 mg/dl), HDL-C: 1.06 mmol/L (41.0 mg/dl), and triglyceride: 0.78 mmol/L (69.0 mg/dl).
She was excluded from the analysis.
Table 10:  Apolipoprotein A-IV 360/ 347 Genotype Distribution and Allele
Frequencies*
Females Males
A-IV 360
1/1 302 (83.7%) 323 (86.6%)
1/2 58  (16.1%) 50 (13.4%)
2/2 1 (0.3%) 0 (0.0%)
A-IV 347
T/T 240 (66.5%) 234 (62.7%)
S/T 107 (29.6%) 119 (31.9%)
S/S 14 (3.9%) 20 (5.4%)
* Allele frequencies for apo A-IV 360 of 1 and 2 in females are 0.92 and 0.08, and in males are 0.93 and 0.07,
respectively. Allele frequencies for apo A-IV 347 of T and S in females are 0.81 and 0.19, and in males are 0.79
and 0.21, respectively.
Concerning the A-IV 347 polymorphic site, 66.5% of the women and 62.7% of the men were
homozygous for the common threonine (T) allele, 29.6% and 31.9% were heterozygous (T/S),
while 3.9% and 5.4% of women and men were homozygous for the rare serine (S) allele,
respectively.
Table 11 shows the genotype distribution and allele frequencies of the LPL Hind III
polymorphism.  In females, 43.8% and in males 50.1% carried the H+/+ wildtype, 44.0% of the
females and 42.4% of the males were heterozygous (H+/-), while 12.2% of the females and 7.5%
of the males were homozygous for the rare H- allele.  Therefore, the allele frequencies of H+ and
H- in females were 0.71 and 0.29, and in males 0.66 and 0.34, respectively.
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Table 11:  Lipoprotein Lipase Hind III Genotype Distributions and Allele
Frequencies*
Genotype Females Males
H -/- 26 (7.5%) 43 (12.2%)
H +/- 147 (42.4%) 155 (44.0%)
H +/+ 174 (50.1%) 154 (43.8%)
* Allele frequencies for H+ and H- for females were 0.71 and 0.29, and for males, they were 0.66 and 0.34,
respectively.
The combined data are consistent with the concept that all genotype distributions and allele
frequencies of the various polymorphisms are similar in men and women.
Effect of Apolipoprotein E Genotype on Glucose and Lipid Parameters
Data on biochemical variables by apo E genotype are provided in Table 12.  Females and males
with the apo E2 allele had 32% and 27% higher apo E values than those with the apo E3/3
genotype (p<0.0001), while subjects with the apo E4 allele had 33% and 18% lower values than
the apo E3/3 group (p<0.0001), respectively.
As in many studies with females and males, there were clearly higher total cholesterol levels in
subjects with the apo E4 allele than in those with the apo E 3/3 genotype, and lower values were
seen in those carrying the apo E2 allele.  This was also true for LDL cholesterol.  In the case of
LDL cholesterol for females, those carrying the apo E2 allele had significantly (p<0.05) lower
LDL cholesterol levels, at 2.83 mmol/L, than those carrying the apo E4 allele, with a mean value
of 3.31 mmol/L.  A similar finding was noted in males, but here those carrying the apo E2 allele
had significantly lower LDL cholesterol levels than subjects with the apo E3/3 genotype.
42
Table 12:  Apolipoprotein E Genotype and Biochemical Parameters*
Females
(n = 354)
Males
(n = 359)
E2+
(n = 42)
E3/3
(n = 213)
E4+
(n = 98)
E2+
(n = 53)
E3/3
(n = 233)
E4+
(n = 73)
Apo E (14.5 ± 4.4) †‡ (11.0 ± 4.8) (8.3 ± 3.0) † (14.3 ± 5.0) †‡ (11.3 ± 4.3) (9.6 ± 4.0) †
Total Cholesterol 5.16 ± 1.22 ‡
(199.3 ± 47.1)
5.53 ± 1.08
(213.3 ± 41.6)
5.80 ± 0.97
(223.7 ± 37.3)
5.14 ± 1.02
(198.4 ± 39.3)
5.40 ± 1.12
(208.5 ± 43.2)
5.56 ± 1.28
(214.8 ± 49.4)
LDL-C 2.83 ± 1.13 ‡
(109.1 ± 43.4)
3.14 ± 0.88
(121.2 ± 34.0)
3.31 ± 0.88
(127.9 ± 33.9)
2.92 ± 0.86 †
(112.6 ± 33.1)
3.26 ± 0.95
(125.7 ± 36.8)
3.33 ± 0.85
(128.5 ± 32.9)
HDL-C 1.57 ± 0.30
(60.5 ± 11.7)
1.58 ± 0.40
(60.9 ± 15.4)
1.71 ± 0.41 §
(65.8 ± 15.8)
1.32 ± 0.33 †‡
(50.9 ± 12.7)
1.21 ± 0.32
(46.8 ± 12.4)
1.20 ± 0.29
(46.2 ± 11.1)
Triglyceride 1.68 ± 0.64
(148.5 ± 56.4)
1.75 ± 0.95
(154.6 ± 84.0)
1.71 ± 0.89
(151.2 ± 78.9)
1.97 ± 1.73
(174.6 ± 114.4)
2.10 ± 1.14
(185.6 ± 100.5)
2.29 ± 1.52
(207.7 ± 134.5)
TC/HDL ratio 3.38 ± 0.94 3.69 ± 1.09 3.58 ± 0.98 4.11 ± 1.31 † 4.68 ± 1.32 4.81 ± 1.14
Glucose 5.01 ± 1.18 †
(91.6 ± 21.6)
5.45 ± 2.55
(99.8 ± 46.7)
4.87 ± 1.29 †
(89.1 ± 23.6)
6.12 ± 2.48
(111.9 ± 45.3)
5.82 ± 2.38
(106.4 ± 43.5)
6.03 ± 3.02
(110.3 ± 55.2)
* Mean values ± SD in mmol/L, values in parentheses are in mg/dl
§ Significantly different (p<0.05) from apo E3 group and apo E4 group before adjustments
† Significantly different (p < 0.05) from apo E3 group
‡ Significantly different (p < 0.05) from apo E4 group
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With regard to HDL cholesterol, results have to be distinguished between before and after
adjustments were made for age, sex, medications, alcohol, and smoking.  Before adjustments,
females carrying the apo E4 allele had significantly higher HDL cholesterol levels than females
who had the apo E3/3 or E2+ genotypes.  No such difference was observed in men.  However,
after adjustments, significant effects on HDL-C levels appeared in males, while existing effects
disappeared in females.  Males carrying the apo E2 allele had significantly higher levels of HDL-C
compared to men carrying the apo E3/3 or E4+ genotype.  With regard to the TC/HDL
cholesterol ratio, no significant effects of apo E genotype were observed in females.  However,
males with the apo E2 allele had significantly lower TC/HDL cholesterol ratios than subjects with
the apo E3/3 genotype.
For glucose values, there was a trend clearly observed in women, where subjects with the apo E4
and apo E2 alleles had the lowest glucose values, and subjects with the apo E3 allele had the
highest values.  In men, no such clear trend with regard to apo E genotype and glucose levels was
noted.
Data on statistical association of apo E genotype with biochemical variables, after adjustment for
medications, alcohol use, smoking, age, and body mass index, are shown in Table 13.
Table 13:  Adjusted Effects of Apolipoprotein E Genotype on Biochemical
Parameters (p values)*
Females
(n = 361)
Males
(n = 373)
Apo E 0.0001 0.0001
Total Cholesterol 0.021 N.S.
LDL-C 0.032 0.037
HDL-C N.S. 0.012
TC/HDL ratio N.S. 0.004
Triglyceride N.S. N.S.
Glucose 0.002 N.S.
* Adjustment for medications, alcohol use, smoking, age, and body mass index.
Apo E genotype had a significant effect in females on apo E (p<0.001), glucose (p=0.002), total
cholesterol (p=0.021), and LDL cholesterol levels (p=0.032).  In contrast, in males no significant
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effects of apo E genotype were noted for glucose or total cholesterol.  However, a significant
effect was observed for apo E (p<0.0001), LDL cholesterol (p=0.037), and HDL cholesterol
levels (p=0.012), as well as the TC/HDL cholesterol ratio (p=0.004) after these adjustments.
Data comparing the effects of apo E alleles on LDL cholesterol, HDL cholesterol, and triglyceride
values in this population was compared with 495 postmenopausal women and 527 men over age
50 participating in cycle 3 of the Framingham Offspring Study are shown in Table 14.
Table 14:  Comparison with Data from the Framingham Offspring Study*
Females Males
E2+ E3/3 E4+ E2+ E3/3 E4+
LDL-C
Current 2.83 (109) 3.14 (121) 3.31 (128) 2.92 (113) 3.26 (126) 3.33 (129)
Framingham 3.39 (131) 3.81 (147) 4.04 (156) 3.58 (138) 3.81 (147) 3.81 (147)
HDL-C
Current 1.57   (61) 1.58   (61) 1.71   (66) 1.32   (51) 1.21   (47) 1.20   (46)
Framingham 1.48   (57) 1.44   (56) 1.50   (58) 1.14   (44) 1.17   (45) 1.11   (43)
Triglyceride
Current 1.68 (149) 1.75 (155) 1.71 (151) 1.97 (175) 2.10 (186) 2.29 (208)
Framingham 1.32 (117) 1.48 (131) 1.37 (121) 1.71 (151) 1.71 (151) 1.70 (168)
* Comparison with 495 post-menopausal women and 527 men over age 50 participating in cycle 3 of the
Framingham Offspring Study.  Mean values are in mmol/L, values in parentheses are in mg/dl.
These data indicate that the health conscious subjects enrolling in a lifestyle modification program
had lower LDL cholesterol values and higher triglyceride and HDL cholesterol values than those
in Framingham (60).
Effect of Apolipoprotein A-I Genotypes on Glucose and Lipid Parameters
Data on biochemical variables according to gender and -75 bp and +83 bp genotypes, as well as
their haplotypes, are provided in Tables 15 - 17.  The effects after adjustment for age, body mass
index, medications, alcohol use, smoking, and apo E alleles are shown in Table 18.  With regard
to the -75 bp polymorphism, a significant difference between genotype classes was observed in
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females.  Women carrying the A-allele had significantly higher levels of apo B (p=0.016), total
cholesterol (p=0.005), LDL-C (p=0.010), and TC/HDL ratio (p=0.026) compared to G/G
homozygotes.  In men, however, no significant difference between the apo A-I -75 bp genotype
and any of the glucose, lipid, and apolipoprotein parameters was observed.
Table 15:  Effects of Apolipoprotein A-I -75 bp Genotype on Biochemical
Parameters*
Females
(n = 359)
Males
(n = 372)
G/G
(n = 266)
G/A+A/A
(n = 93)
G/G
(n = 263)
G/A+A/A
(n = 109)
Apo A-I (146.7 ± 22.1) (146.4 ± 19.9) (131.6 ± 17.4) (133.1 ± 18.0)
Apo B (107.7 ± 28.4) (113.8 ± 33.1) † (115.6 ± 31.6) (116.4 ± 31.0)
Total Cholesterol 5.50 ± 1.00
(212.5 ± 38.4)
5.72 ± 1.27 †
(220.7 ± 48.9)
5.39 ± 1.16
(208.2 ± 44.6)
5.36 ± 1.09
(207.0 ± 42.1)
LDL-C 3.10 ± 0.84
(119.5 ± 32.4)
3.30 ± 1.10 †
(127.4 ± 42.6)
3.21 ± 0.92
(123.9 ± 35.5)
3.21 ± 0.93
(123.8 ± 35.7)
HDL-C 1.62 ± 0.40
(62.6 ± 15.3)
1.58 ± 0.39
(61.0 ± 15.4)
1.23 ± 0.33
(47.5 ± 12.7)
1.22 ± 0.29
(47.2 ± 11.0)
Triglyceride 1.70 ± 0.87
(150.4 ± 77.1)
1.86 ± 1.00
(167.4 ± 89.0)
2.11 ± 1.29
(186.8 ± 114.4)
2.13 ± 1.13
(188.1 ± 99.7)
TC/HDL ratio 3.57 ± 0.99 3.81 ± 1.16 † 4.61 ± 1.31 4.59 ± 1.29
Glucose 5.15 ± 1.79
(94.2 ± 32.8)
5.50 ± 2.90
(101.5 ± 54.8)
5.87 ± 2.55
(107.4 ± 46.7)
5.86 ± 2.36
(107.6 ± 44.8)
* Mean values ± SD, except for ratios, are in mmol/L, values in parentheses are in mg/dl.
† Significantly different (p < 0.05) from the G/G genotype
Considering that a lot of women were on hormonal replacement therapy, analysis was carried out
excluding women taking those hormones.  The significances for total (p=0.006) and LDL
cholesterol (p=0.026) remained (data not shown).
Concerning the +83 bp polymorphism in the first intron of the apo A-I gene, women exhibited an
association of the rare M2+/- genotype with lower total cholesterol (p=0.036) and glucose
(p=0.000) compared to M2+/+ homozygotes (Table 16).  However, the association with glucose
is mainly due to an interaction with diabetes medication.  In men, levels of apo A-I (p=0.002)
46
were significantly higher in M2+/- carriers when compared to M2+/+ genotypes.  Total
cholesterol (p=0.046) was also higher in M2+/- heterozygotes than in M2+ homozygotes.
Table 16:  Effects of Apolipoprotein A-I +83 bp Genotype on Biochemical
Parameters*
Females
(n = 358)
Males
(n = 372)
M2+/+
(n = 329)
M2+/-
(n = 29)
M2+/+
(n = 335)
M2+/-
(n = 37)
Apo A-I (146.5 ± 21.8) (149.3 ± 17.0) (131.0 ± 17.3) (140.1 ± 15.8) †
Apo B (109.2 ± 112.2) (112.2 ± 30.0) (115.4 ± 30.9) (119.7 ± 37.3)
Total Cholesterol 5.56 ± 1.08
(214.7 ± 41.8)
5.58 ± 1.00 †
(213.4 ± 38.6)
5.35 ± 1.08
(206.6 ± 41.6)
5.65 ± 1.56 †
(218.3 ± 60.2)
LDL-C 3.16 ± 0.92
(122.0 ± 35.7)
3.02 ± 0.98
(116.8 ± 32.8)
3.20 ± 0.93
(123.7 ± 35.9)
3.24 ± 0.84
(125.0 ± 37.3)
HDL-C 1.61 ± 0.40
(62.0 ± 15.4)
1.65 ± 0.35
(64.0 ± 13.5)
1.22 ± 0.31
(47.2 ± 12.1)
1.27 ± 0.34
(49.1 ± 13.2)
Triglyceride 1.73 ± 0.86
(153.0 ± 76.5)
1.89 ± 1.29
(165.2 ± 113.2)
2.10 ± 1.18
(185.5 ± 104.3)
2.28 ± 1.75
(201.8 ± 115.0)
TC/HDL ratio 3.64 ± 1.04 3.55 ± 1.02 4.60 ± 1.27 4.67 ± 1.54
Glucose 5.23 ± 2.15
(95.7 ± 39.4)
5.33 ± 1.99 †
(97.2 ± 35.9)
5.81 ± 2.35
(106.4 ± 43.1)
6.34 ± 3.53
(116.0 ± 64.7)
* Mean values ± SD, except for ratios, are in mmol/L, values in parentheses are in mg/dl.
† Significantly different (p < 0.05) from M2+/+ genotype
Haplotype analysis presented in Table 17 revealed the following results.  Overall, women carrying
the rare alleles of both polymorphisms (G/A M2+/-) had the highest levels of apo B, total and
LDL cholesterol, triglyceride, TC/HDL ratio, and fasting glucose and the lowest levels of HDL-C
compared to the rest of the haplotype combinations. However, only the TC/HDL ratio (p=0.031)
reached statistical significance.  In men, significant differences were observed for apo A-I
(p=0.021) and total cholesterol (p=0.044).  G/G M2+/+ and G/A M2+/+ carriers had significantly
lower apo A-I levels compared to the G/G M2+/- haplotype.  With regard to total cholesterol,
men carrying the G/G M2+/+ or the G/A M2+/- combinations had significantly lower
concentrations than their G/G M2+/- counterparts.
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Table 17:  Effects of Apolipoprotein A-I -75 bp and +83 bp Haplotypes on Glucose,
Lipid, Lipoprotein, and Apolipoproteins in Females*
Females
(n = 358)
G/G M2+/+
(n = 243)
G/A M2+/+
(n = 86)
G/G M2+/-
(n = 22)
G/A M2+/-
(n = 7)
Apo A-I (146.7 +/- 22.4) (146.2 +/- 20.0) (149.3 +/- 16.6) (149.5 +/- 20.2)
Apo B (108.1 +/- 28.8) (112.1 +/- 32.4) (105.4 +/- 24.3) (137.3 +/- 37.7)
Total-Cholesterol 5.52 +/- 1.00
(213.0 +/- 38.6)
5.69 +/- 1.28
(219.7 +/- 49.6)
5.43 +/- 0.93
(207.4 +/- 36.8)
6.04 +/- 1.04
(233.1 +/- 40.3)
LDL-C 3.11 +/- 0.89
(120.1 +/- 32.4)
3.29 +/- 1.12
(127.0 +/- 43.3)
2.98 +/- 0.79
(112.8 +/- 31.8)
3.42 +/- 0.90
(132.2 +/- 34.8)
HDL-C 1.61 +/- 0.40
(62.3 +/- 15.4)
1.58 +/- 0.40
(61.1 +/- 15.3)
1.70 +/- 0.36
(66.0 +/- 13.8)
1.49 +/- 0.28
(57.6 +/- 10.7)
Triglyceride 1.70 +/- 0.88
(151.1 +/- 77.7)
1.79 +/- 0.82
(158.2 +/- 73.0)
1.65 +/- 0.82
(143.3 +/- 71.5)
2.68 +/- 2.12
(237.0 +/- 188.0)
TC/HDL ratio 3.59 +/- 1.00 3.77 +/- 1.15 3.33 +/- 0.84 ‡ 4.25 +/- 1.29
Glucose 5.15 +/- 1.83
(94.2 +/- 33.4)
5.46 +/- 2.89
(99.9 +/- 52.8)
5.12 +/- 1.43
(93.5 +/- 25.6)
5.97 +/- 3.28 †
(109.3 +/- 60.0)
* Mean values +/- DS, except for TC/HDL ratios, are in mmol/L. Values in parenthesis are in mg/dl.
† Significantly different (p<0.05) from G/G M2+/+ haplotype
‡ Significantly different (p<0.05) from G/A M2+/+  and G/A M2+/- haplotypes
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Table 18:  Effects of Apolipoprotein A-I -75 bp and +83 bp Haplotypes on Glucose,
Lipid, Lipoprotein, and Apolipoproteins in Males*
Males
(n = 372)
G/G M2+/+
(n = 231)
G/A M2+/+
(n = 104)
G/G M2+/-
(n = 32)
G/A M2+/-
(n = 5)
Apo A-I (130.2 +/- 17.1) (132.6 +/- 17.8) (140.0 +/- 16.3) † (136.4 +/- 15.4)
Apo B (114.6 +/- 30.8) (117.2 +/- 31.2) (122.5 +/- 38.6) (101.6 +/- 22.1)
Total-cholesterol 5.34 +/- 1.07
(206.0 +/- 41.4)
5.39 +/- 1.09
(208.2 +/- 42.1)
5.80 +/- 1.60 †
(224.0 +/- 61.7)
4.70 +/- 0.90
(181.6 +/- 40.3)
LDL-C 3.19 +/- 0.93
(123.2 +/- 36.0)
3.24 +/- 0.93
(124.9 +/- 35.7)
3.34 +/- 0.81
(129.0 +/- 31.2)
2.63 +/- 0.82
(101.4 +/- 31.7)
HDL-C 1.22 +/- 0.32
(47.2 +/- 12.5)
1.22 +/- 0.29
(47.2 +/- 11.1)
1.28 +/- 0.35
(49.7 +/- 13.7)
1.18 +/- 0.25
(45.4 +/- 9.7)
Triglyceride 2.08 +/- 1.19
(184.1 +/- 105.6)
2.13 +/- 1.15
(188.8 +/- 101.6)
2.33 +/- 1.87
(206.4 +/- 165.7)
1.95 +/- 0.54
(172.8 +/- 47.4)
TC/HDL ratio 4.59 +/- 1.27 4.61 +/- 1.29 4.75 +/- 1.58 4.16 +/- 1.25
Glucose 5.80 +/- 2.34
(106.1 +/- 42.8)
5.84 +/- 2.40
(106.9 +/- 43.9)
6.39 +/- 3.78
(116.9 +/- 69.1)
6.04 +/- 1.33
(110.6 +/- 24.4)
* Mean values +/- SD, except for TC/HDL ratios, are in mmol/L. Values in parenthesis are in mg/dl.
† Significant different (p<0.05) from G/G M2+/+ haplotype
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Table 19:  Adjusted Effects of Apolipoprotein A-I Genotypes and Haplotypes on
Biochemical Parameters (p values)*
Genotype Females Males
Apo A-I -75 bp Apo B (p = 0.016) —
Total Cholesterol (p = 0.005) —
LDL-C (p = 0.018) —
TC/HDL ratio (p = 0.026) —
Apo A-I +83 bp — Apo A-I (p = 0.002)
Total Cholesterol (p = 0.040) Total cholesterol (p = 0.046)
Glucose (p = 0.000) —
Haplotypes — Apo A-I (p = 0.021)
— Total Cholesterol (p = 0.044)
TC/HDL ratio (p = 0.031) —
Glucose (p = 0.050) —
* Adjusted for age, body mass index, medications, alcohol use, smoking, and apo E genotype.
Effect of Apolipoprotein A-IV Genotypes on Glucose and Lipid Parameters
In Table 20 data are presented regarding the relationship of the apo A-IV 360 genotype and
serum glucose, lipid, and apolipoprotein measurements.  The only significant effect noted was that
females with the apo A-IV 1/2 genotype had significantly higher glucose levels (11.9%) than
subjects with the common apo A-IV 1/1 genotype (Table 21).  No such effect on glucose levels
was seen in males.  With regard to lipid, lipoprotein, and apolipoprotein parameters, in particular
apo A-IV and HDL cholesterol levels, no association of the 360 mutation was observed in females
or males, respectively.
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Table 20:  Effects of Apolipoprotein A-IV 360 Genotype on Biochemical
Parameters*
Females
(n = 358)
Males
(n = 372)
1/1
(n = 300)
1/2
(n = 58)
1/1
(n = 322)
1/2
(n = 50)
Apo A-I (146.9 ± 21.5) (146.9 ± 20.6) (132.0 ± 17.0) (130.5 ± 19.3)
Apo A-IV (14.4 ± 4.4) (14.4 ± 3.4) (15.5 ± 4.8) (15.8 ± 5.6)
Apo B (109.4 ± 30.3) (109.4 ± 26.4) (115.8 ± 31.6) (115.6 ± 31.5)
Total Cholesterol 5.56 ± 1.09
(214.6 ± 42.1)
5.60 ± 0.95
(216.3 ± 36.6)
5.39 ± 1.16
(207.5 ± 44.8)
5.35 ± 0.96
(206.6 ± 37.0)
LDL-C 3.15 ± 0.94
(121.5 ± 36.2)
3.17 ± 0.80
(122.4 ± 31.0)
3.22 ± 0.94
(124.1 ± 36.2)
3.16 ± 0.81
(121.9 ± 31.3)
HDL-C 1.61 ± 0.39
(62.0 ± 15.1)
1.64 ± 0.41
(63.2 ± 15.8)
1.23 ± 0.31
(47.6 ± 12.2)
1.19 ± 0.32
(46.1 ± 12.5)
Triglyceride 1.74 ± 0.89
(153.8 ± 78.9)
1.77 ± 0.98
(156.7 ± 86.3)
2.10 ± 1.23
(185.4 ± 108.8)
2.24 ± 1.35
(198.3 ± 119.2)
TC/HDL ratio 3.63 ± 1.05 3.61 ± 1.01 4.58 ± 1.30 4.75 ± 1.28
Glucose 5.14 ± 2.00
(94.0 ± 36.2)
5.76 ± 2.70 †
(105.5 ± 49.5)
5.94 ± 2.54
(108.6 ± 46.4)
5.42 ± 2.16
(99.1 ± 39.6)
* Mean values ± SD, except for ratios, are in mmol/L, values in parentheses are in mg/dl.
† Significantly different from the 1/1 genotype (p < 0.05).
Table 21:  Adjusted Effects of Apolipoprotein A-IV Genotype on Biochemical
Parameters  (p values)*
 Females Males
Apo A-IV 360 Glucose (p = 0.004) —
* Adjusted for body mass, age, medications, alcohol, smoking, and apo E genotype
In Table 22 data is listed on the effect of the apo A-IV 347 mutation on fasting glucose as well as
several other lipid parameters.  No significant association was observed in females or males,
respectively.
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Table 22:  Effects of Apolipoprotein A-IV 347 Genotype on Biochemical Parameters*
Females
(n = 359)
Males
(n = 372)
T/T
(n = 238)
S/T
(n = 107)
S/S
(n = 14)
T/T
(n = 233)
S/T
(n = 119)
S/S
(n = 20)
Apo A-I (145.8 ± 21.4) (149.4 ± 20.4) (144.4 ± 28.3) (132.8 ± 18.4) (129.8 ± 15.4) (132.9 ± 15.2)
Apo A-IV (14.0 ± 4.1) (14.9 ± 4.6) (15.9 ± 3.4) (15.4 ± 4.4) (15.3 ± 5.3) (16.9 ± 8.0)
Apo B (110.2 ± 30.4) (109.1 ± 27.8) (96.3 ± 33.1) (118.5 ± 33.4) (109.7 ± 28.4) (121.4 ± 21.1)
Total  Cholesterol 5.58 ± 1.11
(215.3 ± 42.9)
5.55 ± 1.02
(214.4 ± 39.3)
5.29 ± 0.89
(204.2 ± 34.2)
5.39 ± 1.16
(208.0 ± 44.9)
5.31 ± 1.13
(205.0 ± 43.7)
5.75 ± 0.73
(221.9 ± 28.0)
LDL-C 3.16 ± 0.93
(121.9 ± 35.9)
3.14 ± 0.91
(121.4 ± 35.1)
3.04 ± 0.84
(117.5 ± 32.3)
3.17 ± 0.90
(122.6 ± 34.7)
3.22 ± 1.00
(124.5 ± 38.6)
3.48 ± 0.60
(134.2 ± 23.0)
HDL-C 1.60 ± 0.41
(61.6 ± 15.6)
1.63 ± 0.36
(63.0 ± 13.8)
1.67 ± 0.48
(64.3 ± 18.6)
1.24 ± 0.35
(47.8 ± 13.6)
1.21 ± 0.25
(46.6 ± 9.8)
1.20 ± 0.19
(46.5 ± 7.2)
Triglyceride 1.78 ± 0.96
(157.9 ± 85.0)
1.70 ± 0.79
(150.8 ± 69.5)
1.27 ± 0.67
(112.6 ± 54.1)
2.19 ± 1.38
(194.2 ± 122.4)
1.92 ± 0.92
(170.2 ± 81.3)
2.33 ± 1.15
(205.9 ± 101.9)
TC/HDL ratio 3.68 ± 1.08 3.54 ± 0.93 3.43 ± 1.18 4.60 ± 1.35 4.56 ± 1.23 4.90 ± 1.04
Glucose 5.09 ± 1.56
(93.2 ± 28.6)
5.66 ± 3.10
(103.6 ± 56.7)
4.50 ± 0.66
(82.4 ± 12.0)
5.82 ± 2.36
(106.5 ± 43.2)
5.99 ± 2.77
(109.6 ± 50.6)
5.68 ± 2.40
(104.0 ± 44.0)
* Mean values ± SD, except for ratios, are in mmol/L, values in parentheses are in mg/dl.
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Effect of Lipoprotein Lipase Genotype on Glucose and Lipid Parameters
Data on biochemical variables by gender and LPL Hind III genotype are listed in Table 24.  The
effects of the genetic variation after adjustments are shown in Table 23.  Concerning plasma
glucose levels, no significant difference between genotype classes was observed in females and
males.  With regard to total cholesterol, females showed a significant gene-dosage effect of the
Hind III genotype (p = 0.039).  Women being homozygous for the H- allele had the lowest levels,
women being heterozygous (H+/-) had intermediate levels, and women carrying both H+ alleles
had the highest total cholesterol levels.  The same gene-dosage effect was observed in women
with regard to LDL cholesterol.  While women having the H-/- genotype had the lowest LDL
levels, at 2.87 mmol/L, those having the H+/+ genotype had the highest levels, at 3.27 mmol/L
(p=0.004).  In the male population, no significant difference between the Hind III genotype and
total cholesterol or LDL cholesterol was found.  The same was true for triglyceride levels.
However, with regard to HDL-C, there was a significant association, with H-/- homozygote men
having significantly higher HDL-C levels, at 1.34 mmol/L, compared to their H+/+ counterparts,
at 1.17 mmol/L (p=0.003).  No such association was found in women.
Table 23:  Adjusted Effects of Lipoprotein Lipase Hind III Genotype on
Biochemical Parameters*
Females Males
Total Cholesterol p = 0.039 —
LDL-C p = 0.004 —
HDL-C — p = 0.003
* Adjusted for age, body mass index, medications, alcohol use, smoking, and apo E genotype.
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Table 24:  Effects of Lipoprotein Lipase Hind III Genotype on Biochemical Parameters*
Females
(n = 346)
Males
(n = 351)
H +/+
(n = 174)
H +/-
(n = 146)
H -/-
(n = 26)
H +/+
(n = 154)
H +/-
(n = 154)
H -/-
(n = 43)
Total Cholesterol 5.73 ± 1.11
(221.3 ± 42.7)
5.39 ± 1.03 †
(208.2 ± 39.6)
5.27 ± 1.03
(203.6 ± 39.6)
5.29 ± 1.06
(204.1 ± 41.8)
5.44 ± 1.13
(209.8 ± 43.7)
5.54 ± 1.47
(213.7 ± 56.6)
LDL-C 3.27 ± 0.95
(126.2 ± 36.8)
3.04 ± 0.89 †
(117.5 ± 34.3)
2.87 ± 0.78 †
(110.8 ± 30.1)
3.12 ± 0.92
(120.3 ± 35.6)
3.29 ± 0.96
(126.8 ± 37.2)
3.23 ± 0.80
(124.7 ± 30.8)
HDL-C 1.63 ± 0.40
(62.9 ± 15.6)
1.57 ± 0.40
(60.6 ± 15.5)
1.67 ± 0.31
(64.3 ± 15.1)
1.17 ± 0.25
(45.1 ± 9.7)
1.25 ± 0.31 †
(48.2 ± 12.0)
1.34 ± 0.45 †
(51.8 ± 17.5)
Triglyceride 1.80 ± 0.98
(159.5 ± 87.0)
1.70 ± 0.86
(150.8 ± 76.2)
1.63 ± 0.69
(143.9 ± 60.9)
2.29 ± 1.41
(202.4 ± 125.1)
2.02 ± 1.07
(178.7 ± 94.3)
1.91 ± 1.33
(168.6 ± 117.9)
TC/HDL ratio 3.72 ± 1.10 3.60 ± 1.01 3.24 ± 0.72 4.70 ± 1.26 4.56 ± 1.35 4.43 ± 1.33
Glucose 5.19 ± 2.26
(94.9 ± 41.3)
5.27 ± 1.89
(96.4 ± 34.5)
5.21 ± 2.43
(95.3 ± 44.4)
5.71 ± 2.28
(104.5 ± 41.8)
5.80 ± 2.22
(106.1 ± 40.7)
6.45 ± 3.51
(118.1 ± 64.2)
* Mean values ± SD, except for ratios, are in mmol/L, values in parentheses are in mg/dl.
† Significantly different (p < 0.05) from the H+/+ group
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B. Effects of Apolipoprotein E, A-I, A-IV, and Lipoprotein Lipase
Genotypes on Glucose, Lipid, and Lipoprotein Response to Lifestyle
Intervention
Subjects
Results of the lifestyle intervention on biochemical parameters and body weight are presented in
Table 25.
Table 25:  Effects of Lifestyle Intervention on Biochemical Parameters*
Females
(n = 355)
Males
(n = 360)
Pre Post Percent
Change
Pre Post Percent
Change
Glucose 5.23 ± 2.14
(95.8 ± 39.1)
5.00 ± 1.45 †
(91.6 ± 26.6)
! 1.9% 5.86 ± 2.45
(107.3 ± 45.6)
5.37 ± 1.79 †
(98.2 ± 32.8)
! 1.8%
Total Cholesterol 5.56 ± 1.08
(214.6 ± 41.5)
4.97 ± 1.00 †
(191.8 ± 38.8)
! 10.4% 5.38 ± 1.13
(207.8 ± 43.8)
4.73 ± 0.99 †
(182.6 ± 38.4)
! 11.6%
LDL-C 3.15 ± 0.91
(121.5 ± 35.4)
2.86 ± 0.89 †
(110.5 ± 34.2)
! 12.9% 3.21 ± 0.92
(123.8 ± 35.5)
2.89 ± 0.91 †
(111.6 ± 35.1)
! 8.8%
HDL-C 1.61 ± 0.39
(62.1 ± 15.2)
1.45 ± 0.35 †
(56.1 ± 13.4)
! 8.9% 1.23 ± 0.32
(47.4 ± 12.2)
1.12 ± 0.25 †
(43.1 ± 9.5)
! 7.4%
Triglyceride 1.74 ± 0.90
(154.0 ± 80.0)
1.41 ± 0.62 †
(125.2 ± 54.9)
! 12.9% 2.12 ± 1.25
(187.2 ± 110.2)
1.55 ± 0.67 †
(137.5 ± 59.7)
! 15.4%
TC/HDL ratio 3.63 ± 1.04 3.59 ± 1.06 ! 0.5% 4.60 ± 1.30 4.50 ± 2.39 ! 1.1%
Weight (kg) 76.8 ± 20.5 73.2 ± 21.6 † ! 2.2% 96.3 ± 19.1 94.0 ± 17.7 † ! 2.7%
* Mean values ± SD, except for ratios, are in mmol/L, values in parentheses are in mg/dl.
† Significantly different from baseline (p # 0.001)
While this was a two-week intervention program and the body weight data reflect the total two-
week intervention, blood samples were only drawn eight days into the intervention, so they reflect
approximately one week of intervention rather than two.  It was our understanding that blood
would also be sampled after either two or three weeks of lifestyle intervention.  However, this
was not done, except in isolated cases, because of procedure changes at the Pritikin Longevity
Center.  In females, a significant reduction in serum glucose of 1.9% was noted.  In addition, total
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cholesterol and LDL-C were reduced by 10.4% and 8.4%, while HDL-C and triglycerides were
also reduced by 8.9% and 12.9%, respectively.  The total cholesterol TC/HDL cholesterol ratio
was not significantly altered, with a reduction of 0.5%; however, body weight, like all of the other
parameters, was reduced significantly, by 2.2%.  This represented a mean weight reduction from
76.8 kg to 73.2 kg over the two-week period in these women, which represents a 3.6 kg, or 8 lb.
weight loss.  This is a considerable weight loss in a fairly short period of time.  Very similar
effects were noted in the males.  Serum glucose levels were reduced by 1.8%, total and LDL
cholesterol levels were reduced by 11.6% and 8.8% respectively, (all p<0.001), HDL-C and
triglyceride levels were reduced by 7.4% and 15.7% respectively.  In males the TC/HDL ratio was
reduced by 1.1%, which was not statistically significant.  Similar to the females, the males had a
significant reduction in body weight of 2.7%, going from 96.3 to 93.0 kg, which represented a
mean 3.3 kg weight loss, or approximately 7 pounds.  It is important to stress that body weight
changes were observed over a two-week period, whereas alteration in other parameters, reflect
changes over a one-week period.
In order to ascertain what the effects on response would have been, had the subjects been sampled
at the two-week point, we independently analyzed a subset of 31 individuals (9 females and 22
males) who participated in the three-week program and had blood samples drawn at baseline,
eight days, and at 15 days of the intervention.
The data on the subset of 31 individuals are listed in Table 26.  The mean age for this group was
57.5 years, with an elevated body mass index of 31.9 kg/m2 and a weight of 95.1 kg.  Their
average waist circumference was also increased at 116.0 cm.  With regard to medication, 12.9%
were on cholesterol-lowering medication, 12.9% on medication for diabetes, and 12.9% on
thyroid medication.  In the entire sample, 19.4% were on hormonal replacement, which was all
due to 6 females (66.6%).  Alcohol use with more than one drink per week was noted in 35.5%,
and current cigarette smoking was noted in 12.9%.
Data on their biochemical parameters are presented in Table 27.  In this subset there was no
significant change in glucose, but total cholesterol and LDL cholesterol were reduced significantly
by 12.8% and 13.5% in these 31 subjects.  Similarly, HDL-C was reduced by 9.2% and
triglycerides were reduced by 13.0%.  Moreover, the TC/HDL ratio was reduced by 3.2%.  These
data are consistent with the view that some additional benefit is observed in the second week of
the intervention, especially with regard to LDL cholesterol reduction.
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Table 26:  Subset of 31 Study Subjects*
All Subjects
(n = 31)
Age (years) 57.5 ± 9.2
Body mass index (kg/m2) 31.9 ± 6.5
Height (cm) 171.7 ± 11.0
Weight (kg) 95.1 ± 26.3
Waist (cm) 116 ± 17.2
Cholesterol-lowering medication 4  (12.9%)
Medication for diabetes 4  (12.9%)
Hormonal replacement 6  (19.4%)
Thyroid medication 4  (12.9%)
Alcohol users (>1 drink/week) 11  (35.5%)
Cigarette smoking (current) 4  (12.9%)
* Mean values ± SD, or total numbers of subjects with percentage in parentheses
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Table 27:  Effects of Intervention on Biochemical Parameters at 1 and 2 Weeks in
31 Subjects*
Pre Post I Post II % Difference
Pre to Week 1
% Difference
Pre to Week 2
Glucose 5.62 ± 2.0
(102.8 ±
36.3)
5.46 ± 1.62
(100.0 ±
29.6)
5.69 ± 2.56
(104.2 ±
46.8)
! 2.8% + 1.0%
Total
Cholesterol
5.67 ± 1.39
(218.9 ±
53.5)
5.10 ± 1.39 †
(196.7 ±
53.5)
4.87 ± 1.26 †
(187.8 ±
48.6)
! 9.8% ! 12.8%
LDL-C 3.41 ± 1.13
(131.7 ±
43.6)
3.14 ± 1.19 †
(121.3 ±
46.1)
2.86 ± 1.00 †
(110.4 ±
38.6)
! 7.9% ! 13.5% †
HDL-C 1.31 ± 0.40
(50.6 ± 15.6)
1.13 ± 0.35 †
(43.6 ± 13.5)
1.16 ± 0.29 †
(44.9 ± 11.1)
! 10.9% ! 9.2% †
Triglyceride 2.18 ± 1.24
(193.0 ±
109.3)
1.66 ± 0.83 †
(146.5 ±
73.6)
1.74 ± 0.96 †
(154.4 ±
84.8)
! 17.7% ! 13.0% †
TC/HDL ratio 4.68 ± 1.65 5.80 ± 7.09 4.43 ± 1.92 + 29.8% ! 3.2%
* Mean values ± SD, except for ratios, are in mmol/L, values in parentheses are in mg/dl; data from 31 subjects,
22 males and 9 females, blood drawn at 8 and 15 days of intervention.
† Significantly different (p < 0.05) from baseline or pr  value.
Apolipoprotein E Genotype and Response
Data on the effect of the apo E genotype on fasting glucose, lipid and lipoprotein levels in
response to the dietary and lifestyle intervention is presented in Table 28.  Apo E genotype had no
significant effect on total cholesterol, HDL-C, or triglyceride lowering in either men or women.
Regarding LDL cholesterol response, there was a trend in males, with carriers of the E2+ allele
having the highest (-10.5%), E3/3 genotypes having intermediate (-8.8%), and carriers of the E4+
allele having the lowest (-6.8%) response, but the difference did not reach statistical significance.
However, a statistically significant effect of apo E genotype in males was observed on glucose
lowering.  The 53 subjects who carried the apo E2 allele had a 10.6% reduction in glucose, as
compared to the 233 subjects with the normal apo E3 genotype, who had a +0.8% change in
glucose, in other words, no net effect.  These data suggest that males carrying the apo E2 allele
may be more responsive, with regard to glucose lowering.  No such affect was observed in
females.
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Table 28:  Effects of Apolipoprotein E Genotype in Response to Intervention*
Apo E
Genotype
Females
(n = 353)
Males
(n = 359)
E2+
(n = 42)
E3/3
(n = 213)
E4+
(n = 98)
E2+
(n = 53)
E3/3
(n = 233)
E4+
(n = 73)
Glucose + 0.7% ! 2.9% ! 0.6% ! 10.6% † + 0.8% ! 3.7%
Total Cholesterol ! 11.8% ! 9.8% ! 11.0% ! 12.9% ! 11.6% ! 10.1%
LDL-C ! 12.0% ! 7.5% ! 8.8% ! 10.5% ! 8.8% ! 6.8%
HDL-C ! 9.6% ! 8.1% ! 10.4% ! 7.4% ! 7.3% ! 8.4%
Triglyceride ! 10.3% ! 11.5% ! 16.5% ! 12.4% ! 15.7% ! 15.4%
* Mean percent changes from baseline value
† Significantly different (p < 0.05) from the E3/3 genotype after adjustment for age, body mass index, medications,
alcohol use, and cigarette smoking.
Apolipoprotein A-I Genotypes and Response
Data on the effects of the apo A-I -75 bp genotype are shown in Table 29.  With this genotype no
effects on reductions in glucose, total cholesterol, LDL-C, HDL-C, or triglyceride were noted in
either females or males in this study.  However, it is worth mentioning that a trend was noted for
LDL-C, with A/A homozygote females and males having a greater reduction in LDL-C (14.3%
and 15.3%) as compared to their G/G homozygote counterparts (8.3% and 9.0%), respectively.
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Table 29:  Effects of Apolipoprotein A-I !75 bp Genotype on Response to
Intervention*
Apo A-I !75 bp
Genotype
Females
(n = 359)
Males
(n = 372)
G/G
(n = 266)
G/A
(n = 87)
A/A
(n = 6)
G/G
(n = 263)
G/A
(n = 95)
A/A
(n = 14)
Glucose !1.6% !3.0% !0.9% !1.5% !1.8% !6.8%
Total Cholesterol !10.6% !9.4% !13.8% !11.6% !11.0% !15.1%
LDL-C !8.3% !8.2% !14.3% !9.0% !7.7% !15.3%
HDL-C !9.4% !6.8% !15.6% !7.1% !8.3% !7.7%
Triglyceride !12.9% !13.8% +0.7% !14.6% !18.4% !20.0%
* Mean percent changes from baseline value
Data on the effects of the apo A-I +83 bp genotype are shown in Table 30.  With this genotype,
no effect on reductions in glucose, total cholesterol, LDL-C, HDL-C, or triglycerides were noted
in either females or males.
Table 30:  Effects of Apolipoprotein A-I +83 bp Genotype on Response to
Intervention*
Apo A-I +83 bp
Genotype
Females
(n = 358)
Males
(n = 372)
M2 +/+
(n = 329)
M2 +/-
(n = 29)
M2 +/+
(n = 335)
M2 +/-
(n = 37)
Glucose ! 1.6% ! 5.2% ! 1.2% !4.0%
Total Cholesterol ! 10.5% ! 9.0% ! 11.7% ! 10.9%
LDL-C ! 8.4% ! 7.6% ! 8.8% ! 8.9%
HDL-C ! 9.0% ! 7.5% ! 7.5% ! 6.8%
Triglyceride ! 13.1% ! 10.3% ! 16.1% ! 12.3%
* Mean percent changes from baseline value
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Apolipoprotein A-IV Genotypes and Response
Data on the effects of the apolipoprotein A-IV 360 genotype in response to the intervention are
shown in Table 31, for both females and males.  No significant effects on any of the biochemical
variables in response to lifestyle were noted.  However, looking at the gender difference, it is
worth mentioning that 1/2 heterozygote females had a greater HDL-C response (-10.6%)
compared to 1/2 heterozygote males (-6.0%).  In addition, the same group of women had about
half the reduction of triglyceride levels (-10.5%) compared to their male counterparts (-21.2%).
Table 31:  Effects of Apolipoprotein A-IV 360 Genotype on Response to
Intervention*
Apo A-IV 360 Genotype Females
(n = 358)
Males
(n = 372)
1/1
(n = 300)
1/2
(n = 58)
1/1
(n = 322)
1/2
(n = 50)
Glucose ! 1.8% ! 2.6% ! 1.7% ! 2.6%
Total Cholesterol ! 10.2% ! 11.5% ! 11.8% ! 10.8%
LDL-C ! 8.2% ! 9.5% ! 9.2% ! 6.6%
HDL-C ! 8.5% ! 10.6% ! 7.6% ! 6.0%
Triglyceride ! 13.3% ! 10.5% ! 14.8% ! 21.2%
* Mean percent changes from baseline value
With regard to the effects of the apolipoprotein A-IV 347 genotype, which are listed in Table 32,
no significant association of this genotype on responsiveness to lifestyle intervention was noted,
except for reductions in HDL-C in women.  In this study, the mean reductions in women with the
T/T genotype was 8.6%, in women with the T/S genotype it was 8.4%, while in 14 women with
the S/S genotype, the reduction was almost twice as high at 16.7%.  At the same time, women
with the S/S genotype had by far the lowest triglyceride response (-4.5%) compared to women
with the T/T genotype (-13.5%), but the difference did not reach statistical significance.  No such
effect was observed in males.
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Table 32:  Effects of Apolipoprotein A-IV 347 Genotype on Response to
Intervention*
Apo A-IV 347
Genotype
Females
(n = 359)
Males
(n = 372)
T/T
(n = 238)
T/S
(n = 107)
S/S
(n = 14)
T/T
(n = 233)
T/S
(n = 119)
S/S
(n = 20)
Glucose ! 1.2% ! 4.1% + 3.8% ! 0.4% ! 3.5% ! 8.0%
Total Cholesterol ! 10.5% ! 9.6% ! 13.5% ! 12.1% !10.2% ! 14.1%
LDL-C ! 8.6% ! 7.5% ! 12.0% ! 9.3% ! 7.4% ! 12.3%
HDL-C ! 8.6% ! 8.4% ! 16.7% † ! 8.3% ! 6.1% ! 5.0%
Triglyceride ! 13.5% ! 12.7% ! 4.5% ! 15.8% ! 14.5% ! 22.1%
* Mean percent changes from baseline value
† Significantly different (p < 0.05) from the T/T genotype after adjustment for age, body mass index, medications,
alcohol use, and cigarette smoking.
Lipoprotein Lipase Genotype and Response
Data on the effects of the LPL Hind III genotype are presented in Table 33.
Table 33:  Effects of Lipoprotein Lipase (Hind III) Genotype on Response to
Intervention*
Lipoprotein
Lipase Genotype
Females
(n = 346)
Males
(n = 351)
H +/+
(n = 174)
H +/!
(n = 146)
H !/!
(n = 26)
H +/+
(n = 154)
H +/!
(n = 154)
H!/!
(n = 43)
Glucose ! 0.2% ! 0.9% ! 2.9% ! 3.5% ! 6.2% ! 3.3%
Total Cholesterol ! 9.4% ! 10.6% ! 10.4% ! 10.3% ! 11.4% ! 12.6%
LDL-C ! 12.1% ! 8.4% ! 7.8% ! 9.5% ! 9.3% ! 9.2%
HDL-C ! 5.6% ! 9.0% † ! 9.3% ! 10.3% ! 7.0% ! 6.8%
Triglyceride ! 10.8% ! 12.8% ! 13.0% ! 7.3% ! 16.7% ! 16.7%
* Mean percent changes from baseline value
† Significantly different (p < 0.05) from the H+/+ genotype after adjustment for age, body mass index, medications,
alcohol use, and cigarette smoking.
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No effects of variation at this restriction site on the response or reduction of any of the
biochemical parameters were noted, either in females or males, except for reductions in HDL
cholesterol.  Here, females who were heterozygous for the rare H- allele (H+/-) had a 9.0%
reduction versus a 5.6% reduction in those women carrying the wildtype (H+/+).  Female subjects
homozygous for the H- allele (H-/-) also showed a 9.3% reduction in HDL-C, however, the
difference was not statistically significant, probably due to the small sample size of this group.  In
males, only a trend was seen for triglyceride response.  Men carrying the rare H- allele had greater
reduction (-16.7%) compared to men carrying the H+/+ genotype (-7.3%), but the difference did
not reach statistical significance due to the large variability of triglyceride levels.
It should be noted, however, that these findings must be interpreted with caution, since with
multiple comparisons, the possibility of finding associations by chance are fairly high, especially
with small sample sizes, as in this case.
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C. Effects of Diet and Exercise on Glucose, and Plasma Lipoproteins:
Results of Long-Term Follow up
Subjects
Information on 202 study subjects is provided in Table 34.  The mean age of these subjects was
approximately 61 years.  The mean body mass index in the women was 27.2 kg/m2, and in the
men 29.9 kg/m2, with mean weights being 71.9 kg and 95.1 kg, respectively.  The waist
circumference was substantial, in women being 97.8 cm, and in men being 107.8 cm.
Approximately 20% of both women and men were on cholesterol-lowering medication, another
6% of both genders were on medication for diabetes.  None of the men, but 36.8% of the women,
were on hormonal replacement, specifically estrogen alone or estrogen plus progesterone in post-
menopausal women.  However, menopause status in those women was not assessed.  Another
13.6% of the women, and 9.4% of men were on thyroid medication, and 40.4% of the women and
over half of the men had more than one drink per week, in terms of alcohol intake.  Cigarette
smoking was fairly uncommon, with only 4.3% of the women and 9.5% of the men being current
smokers.
Table 34:  Study Subjects*
Men
(n = 107)
Women
(n = 95)
Age (years) 61.3 ± 10.6 60.6 ± 9.8
Body mass index (kg/m2) 29.9 ± 5.2 27.2 ± 4.9
Weight (kg) 95.1 ± 18.6 71.9 ± 14.2
Waist (cm) 107.8 ± 14.6 97.8 ± 14.6
Cholesterol-lowering medication 22 (20.6%) 19 (20.0%)
Medication for diabetes 6 (5.6%) 6 (6.3%)
Hormonal replacement 0 (0.0%) 35 (36.8%)
Thyroid medication 10 (9.4%) 30 (31.6%)
Alcohol users (>1 drink/week) 57 (53.8%) 35 (40.4%)
Cigarette smoking (current) 10 (9.5%) 4 (4.3%)
* Mean values ± SD or number with percentage of total in parentheses.
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With regard to the effects of lifestyle intervention program on biochemical parameters in men,
data are listed in Table 35.  After eight days of intervention, glucose levels decreased by 10.7%
(p=0.036) and total and LDL cholesterol were reduced by 8.6% and 7.2%, respectively
(p£0.001).  Triglyceride reductions were even greater, at 27.1% (p£0.001).  As has often been
observed with such diets, HDL-C levels were also decreased by this intervention by 4.3%
(p=0.006).  When subjects returned to the program for an evaluation and a second lifestyle
modification, their values were compared at this second baseline time point with the first baseline,
prior to any intervention.  In men, glucose levels were 1.6% lower.  Total cholesterol levels were
5.2% higher (p=0.007), and LDL-C levels were 6.2% higher (p=0.013).  In addition, HDL-C
levels were 6.9% higher (p<0.001), while triglyceride levels were 2.3% lower.  The post-
intervention results obtained on the eighth day of the second intervention again revealed that the
program resulted in significant changes in glucose, total and LDL cholesterol, and triglyceride,
whether this was compared to baseline values for baseline 1 or versus baseline 2.  Only percent
changes and statistics are provided for comparison with baseline 1.  These results are consistent
with the concept that this intervention does not provide lasting effects in men on lowering levels
of glucose, total and LDL cholesterol, and triglyceride.
Table 35:  Effects of Intervention on Biochemical Parameters in Men*  (n = 107)
Baseline 1 Post 1 Baseline 2 Post 2
Glucose 5.63 ± 2.60 5.03 ± 1.15 †
(! 10.7%)
5.54 ± 1.87
(! 1.6%)
5.18 ± 1.43 †
(! 8.0%)
Total Cholesterol 4.98 ± 1.03 4.55 ± 0.93
(! 8.6%)
5.24 ± 1.14 †
(+ 5.2%)
4.65 ± 0.94 †
(! 6.6%)
LDL-C 2.92 ± 0.85 2.71 ± 0.80 †
(! 7.2%)
3.10 ± 0.96 †
(+ 6.2%)
2.81 ± 0.90
(! 3.8%)
HDL-C 1.16 ± 0.28 1.11 ± 0.29 †
(! 4.3%)
1.24 ± 0.33 †
(+ 6.9%)
1.13 ± 0.27
(! 2.6%)
Triglyceride 2.14 ± 1.67 1.56 ± 0.72 †
(! 27.1%)
2.09 ± 1.26
(! 2.3%)
1.52 ± 0.64 †
(! 29.0%)
* Mean values ± SD in mmol/L, conversions from mg/dl were division by 38.6 for choleste ol, 88.5 for triglyceride,
and 18.3 for glucose; percent values are percentage change in mean value from baseline 1.
† Significantly different (p < 0.05) from baseline value.
We see the same pattern in the women with intervention resulting in significant reductions in all
biochemical parameters, except for glucose, which only was reduced by 2.5% (Table 36).  Total
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cholesterol was reduced by the intervention by 11.4% (p£0.001), triglycerides were decreased by
21.1% (p£0.001), LDL-C was lowered by 11.1%, and HDL-C was lowered by 7.7%, both
p<0.001.  Therefore, just over a week of intervention had a fairly significant effect on lowering all
of the lipid parameters.  Despite this, when subjects returned on average approximately two years
later, no significant differences were observed with regard to any of the parameters, in terms of
lowering, when one compared the second baseline values with the first baseline values.  The only
exception was HDL-C, which was 7.1% higher (p<0.001).  The modest glucose reduction that
was noted was in fact retained, but this was only 2.3%.  Total cholesterol was essentially
unchanged, with values that were 2.0% higher, triglyceride levels that were 9.8% lower than the
first baseline, and LDL-C values that were also unchanged, being only 0.9% higher than the first
baseline.
Table 36:  Effects of Intervention on Biochemical Parameters in Women*  (n = 95)
Baseline 1 Post 1 Baseline 2 Post 2
Glucose 5.22 ± 1.74 5.09 ± 1.52
(! 2.5%)
5.10 ± 1.83
(! 2.3%)
5.00 ± 1.59
(! 4.2%)
Total Cholesterol 5.61 ± 0.95 4.97 ± 0.96 †
(! 11.4%)
5.72 ± 0.94
(+ 2.0%)
5.03 ± 0.94 †
(! 10.3%)
LDL-C 3.23 ± 0.88 2.87 ± 0.86 †
(! 11.1%)
3.26 ± 0.85
(+ 0.9%)
2.88 ± 0.88 †
(! 10.8%)
HDL-C 1.56 ± 0.41 1.44 ± 0.40 †
(! 7.7%)
1.67 ± 0.38 †
(+ 7.1%)
1.48 ± 0.33 †
(! 5.1%)
Triglyceride 1.94 ± 1.51 1.53 ± 0.66 †
(! 21.1%)
1.75 ± 0.94
(!9.8 %)
1.42 ± 0.59 †
(! 26.8%)
* Mean values ± SD in mmol/L, conversions from mg/dl were divisor by 38.6 for choleste ol, 88.5 for triglyceride,
and 18.3 for glucose; percent values are percentage change in mean value from baseline 1.
† Significantly different (p < 0.05) from baseline value.
Not surprisingly, the second intervention, after eight days provided the same results as the first
one, with significant reductions in total, LDL, and HDL cholesterol as well as triglyceride.
However, as for men, these data are consistent with the concept that this intensive lifestyle
intervention resulted in no lasting effects on these biochemical parameters related to heart disease
risk.
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Discussion
A. Effects of Apolipoprotein E, A-I, A-IV, and Lipoprotein Lipase
Genotypes on Baseline Levels of Glucose, Lipid, Lipoprotein, and
Apolipoproteins
Subjects
It has been a well-known fact that significant differences in biochemical parameters exist between
females and males.  This study clearly demonstrated that data analysis should be carried out in a
gender specific way.  Anthropometric measurements as well as all the various biochemical
parameters, except for LDL-C, were significantly different in men and women.  This result is
consistent with previous observations (242) regarding a significant gender difference, especially
for HDL-C and Apo A-I.  Females had significantly higher levels of both traits compared to
males.  The reason for this difference appears to be due to a significantly higher production rate of
apo A-I in females, presumably due to hormonal influences.  Estrogen administration has been
shown to increase the production rates of HDL-C and apo A-I (243,244).  In addition, Seishima
et al. (245) reported that both apo A-I expression and metabolism are affected by endogenous sex
hormones.  More recently, studies have indicated that the thyroid hormone triiodothyronine (T3)
is another potent mediator of expression of various genes (246,247).  In our study population, it
was interesting to notice that a relatively large percentage of females were either on sex hormones
and/or thyroid medication.  This fact may partly explain the higher levels of apo A-I and HDL-C
as well.  In addition, differences in environmental background, lifestyle, and dietary intake are also
reasons for such a gender effect.
Furthermore, a gene-gender interaction was observed, with women being affected differently by
various genetic variations as compared to men.  Those differences, however, will further be
discussed in each of the following sections.
Apolipoprotein E
Apo E genotype frequencies in this population of middle-aged and elderly men and women, were
similar to those reported for other Caucasian populations (41,49,57,59).  These results were also
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consistent with previous apo E phenotype data as determined by IEF by other groups as well as
by us (49,54-60).
In this study population significant allele effects of the apo E genetic variability on plasma
lipoproteins and apoproteins were observed.  Similar to others studies (248-251), our data clearly
indicated that apo E genotype has a significant effect on LDL cholesterol in both men and women,
such that subjects with the apo E2 allele had the lowest LDL cholesterol levels, those with the apo
E3/3 genotype had intermediate levels, and subjects carrying the apo E4 allele had the highest
LDL cholesterol levels (Figure 12).
Figure 12
In this scenario it did appear that the apo E2 allele caused a greater reduction in LDL cholesterol
as compared to the E3/3 genotype than the apo E4 allele did in raising LDL cholesterol.  The
effect of the apo E isoforms on LDL concentrations is thought to be mediated by the LDL-
receptor (49,248,251,252).  In individuals homozygous for the apo E2 allele, low LDL
cholesterol levels have been reported to be associated with both a decreased conversion of VLDL
to LDL and an accelerated catabolism of LDL particles (252-255).  This latter effect is mediated
by two mechanisms: [1] the upregulation of the LDL-receptor due to the lower intracellular
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cholesterol availability associated with the deficient uptake of remnants and [2] the increased
availability of the hepatic LDL-receptors due to the lack of competition for binding by
chylomicron and VLDL remnants.
The physiological effects of apo E4 are felt to be opposite to those of apo E2.  In individuals
carrying the E4 allele, more cholesterol from apo E-containing lipoproteins is internalized by the
hepatocytes.  This increase in intracellular cholesterol levels is compensated for by a down-
regulation of the amount of LDL-receptors.  Furthermore, a more efficient conversion of VLDL
remnants to LDL cholesterol has been observed, resulting in a higher LDL production rate.  All
these metabolic effects are responsible for the increase in plasma LDL cholesterol.
Whereas the apo E allele effect on serum cholesterol levels is almost constant in most populations,
controversial results concerning triglyceride levels are found in the literature.  Since triglycerides
vary widely among and within individuals (66,265), this variability could mask a clear apo E
genotype effect.  Dallongeville et al. (58) as well as other studies (61,63,65,66,69) documented a
significant association between apo E2 and E4 and higher triglyceride levels compared to E3/3
homozygotes.  In our study, however, no such association in either gender was observed.  This is
in agreement with a previous meta-analysis of Davignon et al. (49) combining results of 7 studies.
In this large data set they could not detect a relationship between the apo E genotype and
triglyceride concentrations.  Similar results were published not only in the Framingham Offspring
population (60), but also in several other populations (59,67,257-259).
With regard to HDL cholesterol, we observed a significant effect in men, with men carrying the
apo E3/3 genotype and the apo E4 allele having lower HDL cholesterol levels, as compared to
men carrying the apo E2 allele.  This result is somewhat different compared to previous reports.
While several investigators failed to show an association between the apo E gene locus and HDL
cholesterol levels (60,65,66,258,260-263), others did report a similar positive effect of the apo E2
allele in a Finnish population (67) as well as in students from 11 European countries (61).  Hegele
et al. (259) and Kamboh et al. (59) could only detect an association in the female population of
the Hutterite Brethren and non-Hispanic Whites, respectively.  In their studies, women carrying
the E2 allele had higher levels and those carrying the E4 allele had lower HDL-C levels compared
to the E3/3 wildtype.  No such effects were noted in men.  Some investigators have reported that
the apo E2 allele is associated with increased HDL-apo E (264) or HDL cholesterol levels
(59,257).  The mechanism of this relation still remains to be clarified.  Recently, in vivo (265) and
in vitro (266) studies have shown that apo E plays an important role in the regulation of
cholesterol ester transfer protein (CETP).  Assuming that CETP activity is affected by the apo E
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polymorphism, the interrelation between apo E genotype and HDL concentrations might be
reasonable.  Another possible explanation may be the involvement of apo E in the extracellular
efflux of cholesterol (267).  If the efflux rate varies with the apo E genotype, it might have a
corresponding effect on HDL cholesterol levels.
Not surprisingly, men with the apo E2 allele had significantly lower TC/HDL ratios than other
apo E genotype groups.  This is in accordance with the findings of investigators suggesting that in
the population at large the E4 allele exerts a deleterious effect and, to a lesser extent, the E2 allele
exerts a protective effect on risk for CHD (63,261,268-271).
Several studies have shown significant associations between plasma apo E levels and apo E
isoforms (61,63,66,24,248,263) and genotypes (272).  In agreement with those studies, we noted
a striking effect of the apo E genotype on plasma apo E levels in both men and women, those with
the apo E2 allele had the highest levels, and those with the apo E4 allele had the lowest levels.
These differences were highly significant (p<0.0001), and indicate that the apo E locus is a major
factor controlling apo E levels in plasma (272) (Figure 13).
Figure 13
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These data are consistent with the concept that apo E2 is catabolized more slowly than apo E3
and apo E4, as has been previously reported (273-275).  Moreover, it is known that apo E is
essential for the catabolism of triglyceride-rich lipoproteins since in its absence (familial apo E
deficiency), the clearance of TRL apoB-100 and apoB-48 is markedly delayed, resulting in
triglyceride-rich lipoprotein remnant accumulation (276).
Furthermore, a significant relationship was detected between apo E genotype and glucose levels in
females only, after adjusting for the effects of medication, alcohol use, smoking, age, and body
mass index.  Women carrying the apo E2 and apo E4 alleles had lower glucose levels than those
with the apo E3/3 genotype.  These results confirm recent data reported by Kataoka et al. (69)
who found the same association between fasting glucose and apo E genotype in diabetic American
Indian women.  E3/3 homozygotes had higher fasting glucose levels compared to women carrying
the E2 and E4 alleles.  Kamboh et al. (59), however, failed to show such an effect in Hispanic and
non-White Hispanic men and women, respectively.  How glucose could be related to apo E
genotype remains to be determined.
Our overall data are consistent with the concept that the apo E genotype has a major effect in
determining plasma apo E and lipid levels. The apo E2 allele is associated with increases in apo E
levels in both men and women, decreases in LDL cholesterol in both men and women, and
decreases in glucose in women.  In contrast, the apo E4 allele is associated with decreases in the
apo E levels and increases in LDL cholesterol in both men and women, and decreases in glucose
levels in women only, as compared to subjects with the common apo E3/3 genotype.
Apolipoprotein A-I
High plasma HDL cholesterol and apo A-I levels have been found to be protective against CAD
(104,105).  Therefore, it is of public interest to investigate the environmental and genetic factors
determining those levels.  The apo A-I gene itself and in particular the promoter region with its
sequences implicated in the transcriptional control, is a prime candidate for such investigation.
Mutations in this region could affect transcription rates, and thus alter hepatic and/or intestinal
synthesis and secretion rates, which could affect levels of apo A-I and HDL cholesterol.  The aim
of the present study was to examine the association of polymorphisms at position -75 bp and +83
bp of the apo A-I gene on various lipid, lipoprotein, and apolipoprotein traits in a large
population, and in a gender specific way.
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Conflicting reports as to the significance of the G to A mutation at -75 bp in the promoter region
of the apo A-I gene on plasma on HDL-C and apo A-I levels have been accumulating in the
literature (see Table 1).  The earliest study by Pagani et al. (132) documented that the A-allele
was over-represented in Italian women in the highest decile of HDL levels, but not in Italian men
in the corresponding decile.  Furthermore, Xu et al. (138) reported that the G/A mutation was
associated with higher HDL-C and apo A-I levels in Italian boys, but not in girls.  Similar effects
of the A-allele on HDL-C and/or Apo A-I have been reported in males from England (131),
Belgium (137), and Finland (136).  In two of those studies (134,140), however, this effect of the
A-allele on apo A-I levels was restricted to non-smoking men only.  The investigators did not
detect such an effect in women or male smokers.
In contrast, our study, carried out in 734 men and women, did not show significant associations of
the A-allele with higher HDL-C or apo A-I.  This is in agreement with some recent results, in
which no effect of the -75 bp polymorphism was evident (143-147,150).  Barre et al. (143)
studied 22 Caucasian nuclear families and found no significant difference between individuals with
the A-allele and their G/G siblings.  Our own previous study showed no difference in allele
frequencies in males and females with HDL values below the 25th or above the 75th percentile of
the population distribution (147).  Furthermore, Minnich et al. (135), who described higher levels
of HDL-C and A-I in heterozygous French females, concluded that there was no direct effect of
the A-allele, but that a bimodal distribution of HDL-C, a missing gene-dosage effect, and
segregation of hyperalphalipoproteinemia with a subset of the A-allele family members could be
the cause of the association.
In general, however, the G/A variation is believed to have a direct effect on levels of HDL-C and
apo A-I.  Sastry et al. (277) described in in vitro studies, that DNA segments, located between -
2052 and -192 bp and between -256 and -41 bp upstream from the transcription start site of the
human apo A-I gene, are necessary for maximal levels of apo A-I expression in the intestine and
liver, respectively.  Furthermore, different cis- (277-279) and trans-acting factors (280) involved
in the expression of the apo A-I gene have been identified.  DNase I footprinting experiments
have identified four protein binding domains between -220 and +17 bp, including one at -128 to -
77 bp, which is in close proximity to the -75 bp polymorphic site (281).  Therefore, it is
hypothesized that the base substitution from G to A modifies the affinity for transcription factors
binding to this region and thereby affects the synthesis or secretion of apo A-I (134).  Indeed,
Angotti et al. (282) noted that the presence of the A-allele increased the basal transcriptional
efficiency of the apo A-I promoter due to a lower affinity of a 90 kDa binding factor.  These
authors suggest that the G to A substitution in the promoter region results in a more efficient
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expression and ultimately in higher apo A-I levels in individuals carrying the A-allele than the G-
allele.  In contrast, Smith et al. (283) measured the promoter activity of the two different alleles in
vitro by linkage to a chloramphenicol acetyltransferase (CAT) reporter gene followed by
transfection into the HepG2 human hepatoma cell line.  These investigators noted a 68%
reduction in promoter activity of the A-allele compared to the G-allele, which in vivo accounted
for the significantly lower apo A-I production rate (by 11%) in G/A heterozygotes.  In spite of
this apparent effect of the -75 bp polymorphism on the apo A-I production rate, they did not
observe an effect on levels of HDL-C or apo A-I.  Additional in vitro studies (284) failed to show
different promoter activities from the G or A constructs when tested under basal conditions or
after stimulation with steroids or retinoic acid.  Therefore, they suggest that the G/A
polymorphism does not directly affect the transcriptional efficiency of the apo A-I gene,
supporting the findings from this and previous studies (143-147,150).
We found in women a significant association between the A-allele and higher levels of apo B,
total and LDL cholesterol, as well as the TC/HDL ratio compared to G/G homozygotes (Figure
14).
Figure 14
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These results are unexpected considering that several studies assigned a beneficial effect to the A-
allele.  However, looking at more recent studies, similar results have been documented in the
literature, but in a smaller number of subjects.  Xu et al. (138) described that the G/A substitution
was associated with higher plasma levels of total cholesterol, LDL-C, and apo B in 111 Italian
boys, but not in girls.  More recently, Mata et al. (150) observed in 69 subjects carrying the A-
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allele a higher plasma cholesterol, LDL-C and triglyceride than in those with the G/G genotype.
Somewhat related results were published by Matsunaga et al. (285) who documented in healthy
Japanese students carrying the G/A genotype significantly lower plasma concentrations of apo A-I
than G/G homozygotes.  In CAD patients, Wang et al. (146) reported a higher likelihood of
having one or more significantly diseased vessels (>50% luminal obstruction) in homozygotes for
the -75 bp substitution compared to G/G homozygotes.
The physiological explanations that could reconcile the controversial findings described above
remain elusive.  It has been proposed that the G to A exchange could be a functional mutation and
therefore have a direct effect on the phenotypes examined.  Alternatively, it has been proposed
that this polymorphism maybe a marker in linkage disequilibrium with one or more functional
mutations either in close proximity or at a nearby gene.  In this study, we found linkage
disequilibrium between the -75 bp and the +83 bp polymorphisms.  No subject carrying A/A and
the rare M2- allele was found, which confirms previous findings (142) and indicates that the +83
bp mutation is linked to the G-allele only.  It is interesting to note that in females the presence of
the rare M2- allele appeared to potentiate the already existing negative effect of the A-allele.
While women carrying the G/A M2+/+ haplotype already showed higher levels of apo B, total and
LDL cholesterol compared to their G/G M2+/+ counterparts, women with the additional rare
allele of the +83 bp mutation (G/A M2+/-) exhibited an even greater increase in all those levels.
However, differences did not reach statistical significance, probably due to the small sample size.
Another strong linkage disequilibrium between the A-allele (G/A substitution) and the X2-allele
(XmnI RFLP) has been described (137,286).  The XmnI polymorphism is also located in the 5´
flanking region of the apo A-I gene and the X2-allele has been reported to be associated with
higher plasma levels of total and LDL cholesterol in healthy men (287).  In addition, the X2-allele
is found to be associated with a higher frequency in individuals with combined hyperlipidemia
(286).
Another possible explanation is the linkage with the SstI polymorphism located in the 3´uncoding
region of the apo C-III gene.  Apo C-III is an inhibitor of lipoprotein lipase and is involved in the
metabolism of triglyceride-rich lipoproteins.  Thus, genetic variations affecting plasma apo C-III
levels may be responsible for the effect on plasma LDL-C levels through the metabolism of
VLDL.  In Germans, a significant association between the S1S2 genotype and higher serum
cholesterol levels has been described (288).  Moreover, Lopez-Miranda et al. (289) observed that
the interaction between the SstI and the -75 bp polymorphism had an additive effect on changes in
total cholesterol, LDL-C, and apo B induced by diet.  Furthermore, Dallinga-Thie et al. (290,291)
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found linkage disequilibrium between all three of those polymorphisms (G/A substitution, XmnI
RFLP, and SstI polymorphism).  They reported associations between higher frequencies of rare
alleles (A, X2, S2) and elevated levels of plasma cholesterol, triglycerides, LDL-C, apo B, and
apo C-III.  Their quantitative sib-pair analysis (290) revealed linkage between the rare A-allele of
the -75 bp polymorphism and LDL-C levels.  Therefore, it could be hypothesized that the
differences in plasma LDL-C levels in subjects with different apo A-I -75 bp genotypes are
mediated through an effect on plasma apo C-III levels.
As previously reported (see Table 1), we found gender-related differences for the associations
between the A-allele and some of the lipid traits examined.  Some studies only observed an effect
of the A-allele in men (134,137,138,140), whereas others found this association only in females
(132,139,135).  Some potential explanations for this gender differences may be found in
interactions of environmental and life-style factors with the different genotypes.  It is known that
factors such as age, gender, body mass index, diet, alcohol consumption, smoking, physical
exercise, and exogenous hormones as well as lipid lowering drugs (115-117,292) play a major
role in the variance of glucose and lipid traits.  In a population-based study, Moll et al. (120)
calculated that those factors might account as much as 20% of the variance of the apo A-I levels.
In this study, all these factors were present.  Even though, we considered these in the statistical
analysis, there still is a chance that such factors could have influenced the results.  Furthermore,
multivariate analyses were carried out, which could result in some significant associations being
observed due to chance.
Additional analyses were carried out, excluding women that were taking sex hormones.
However, genotype associations with total cholesterol and LDL-C levels still remained significant
(data not shown).
Regarding the +83 bp polymorphism located in the first intron of the apo A-I gene very few
studies have been reported and, like those examining the -75 G/A mutations, they show
conflicting results (141,142,146,148) (see Table 2).  Wang et al. (141) observed in 243 healthy
Caucasians a significant effect of the rare M2- allele on HDL-C, with M2-/+ adults and children
having higher levels compared to M2+/+ subjects.  Moreover, they also detected linkage
disequilibrium between the -75 bp promoter and the +83 bp polymorphisms.  Their joint effect on
HDL-C levels was also significant and individuals with rare alleles at both sites (A-allele and M2-
allele) had the highest HDL-C levels.  This is somewhat in agreement with our results, in which
males carrying both rare alleles had the highest apo A-I levels.  However, these data, especially
the results on the linkage disequilibrium, have to be evaluated with care as only a small number of
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subjects were in the various groups.  Surprisingly, a second study by Wang et al. (146), screening
644 CAD patients, revealed opposite results.  Patients carrying the rare +83 bp allele were not
associated with higher levels of HDL-C or A-I.  Instead, they were even more likely to have
increased severity of CAD as well as a positive family history of CAD.  Kamboh et al. (142), on
the other hand, demonstrated in males non-smokers with the M2+/- genotype higher levels of apo
A-I compared to the M2+/+ wildtype.  In women, they noted a significant difference in HDL-C
levels, with M2+/- heterozygotes having higher levels than M2+/+ homozygotes.  In the most
recent study (148) investigating 69 subjects with heterozygous familial hypercholesterolemia, no
association with altered lipids or with dietary response to an NCEP Step I diet was detected.
Our own results revealed a strong association of the +83 bp polymorphism on apo A-I in men,
shown in Figure 15.
Figure 15
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Heterozygotes (M2+/-) had significantly higher apo A-I levels than M2+ homozygotes.
Furthermore, males showed a weak significance of the rare M2- allele with higher total
cholesterol levels.  In females, the M2- allele noted a similar weak effect on total cholesterol, but
in the opposite direction.  Women carrying the rare allele had lower levels of total cholesterol than
their M2+/+ homozygous counterparts.
The metabolic explanation, however, can only be speculative.  The +83/84 bp mutation/s located
in the first intron of the apo A-I gene might have an effect on mRNA stability, with the T and/or
A substitutions being more stable than the wildtype.  Alternatively, as suggested for the -75 G/A
polymorphism, the +83 bp polymorphism maybe in linkage disequilibrium with another functional
polymorphism.  Another possible explanation is the methylation hypothesis.  Schemer et al. (293)
reported that the methylation pattern of the 5´ region of the apo A-I gene was negatively
correlated with the extent of its expression.  While a hypomethylated 5´ region is found in tissues
expressing the gene (liver), heavy methylation is found in non-expressing tissues (kidney).
Therefore, it is believed that the T and/or A mutations at +83 bp may lead to an enhanced
demethylation causing more cells to express the apo A-I gene.  However, it still remains to be
determined if hormone levels affect this process and therefore explain the gender differences
observed.
In conclusion, our data is consistent with the concept that the apo A-I -75 bp does not affect
levels of HDL cholesterol and apo A-I in males or females.  Furthermore, our data does not
support the hypothesis that the rare A-allele of the -75 bp mutation has a beneficial effect since
higher levels of apo B, total cholesterol, and LDL-C and an TC/HDL ratio was noted in females
carrying the A-allele compared with G/G homozygotes.  With regard to the +83 bp mutation, the
rare M2- allele seems to have an effect on apo A-I levels with M2+/- heterozygotes having higher
levels than their M2+/+ counterparts.  The linkage disequilibrium, found between the two
polymorphisms, seems to exhibit a potentiating effect in women.  Women carrying both rare
alleles (G/A M2+/-) had the highest levels of apo B, total and LDL cholesterol, and TC/HDL
ratio, and the lowest levels of HDL-C compared to any other haplotype.  In men, on the other
hand, the addition of the rare M2- allele exhibited a positive effect, due to a greater increase in
apo A-I and HDL-C levels compared to men without the +83 bp mutation.
Apolipoprotein A-IV
For a number of years, special interest has been focused on apo A-IV, because of its potential role
in the reverse cholesterol transport and triglyceride-rich lipoprotein metabolism.  In this study, we
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investigated the effects of two different apo A-IV gene polymorphisms on fasting glucose, lipid,
lipoprotein, and apolipoprotein levels in a large population.  One of the polymorphisms is located
at position 360 and is due to substitution of His for Gln and the other one is located at codon 347
and is caused by an amino acid exchange of Thr to Ser in the mature protein.  Using polymerase
chain reaction (PCR) and restriction isotyping, instead of two-dimensional electrophoresis or
isoelectric focusing, ensured an unambiguous typing of the known isoforms and prevented
mimicking of other isoforms with the same charge properties.  Additionally, it is a faster and less
expensive way of analyzing these two polymorphisms on a large data set.  The frequencies of the
various alleles, however, are comparable to the ones analyzed by phenotyping (see Table 3).
With regard to the apo A-IV 360 polymorphism previous metabolic and physiological
experiments revealed considerable differences between the two most common isoforms apo A-IV-
1 and apo A-IV-2.  Weinberg et al. (294) reported that the apo A-IV-2 isoprotein has more alpha-
helical structure, higher binding affinity for phospholipids, and greater ability to activate LCAT
compared to the apo A-IV-1 isoprotein.  In addition, apo A-IV-2 has been observed to be a more
potent activator of lipoprotein lipase than apo A-IV-1 (188).  Rader et al. (295) found that the
fractional catabolic rate of the apo A-IV-2 is slower than that of the apo A-IV-1 wildtype.  All
these structural and functional differences provided support for the concept that apo A-IV-1 and
apo A-IV-2 may have different in vivo metabolisms, which may affect plasma levels of lipids,
lipoproteins, and apo A-IV levels in a differential manner.
Population studies, however, have revealed mixed and even contradictory results (see Table 3).
Some reports have documented significant associations between the apo A-IV 1/2 genotype and
higher HDL cholesterol (185,186,296,297) and lower triglyceride (186) levels while others have
reported that subjects carrying the 2-allele had significantly lower concentrations of HDL, HDL2,
and HDL3 cholesterol (187) and higher triglyceride levels (298).  Furthermore, reports have been
published showing that subjects with the A-IV 1/2 genotype had significantly lower levels of Lp
(a) (197,299), higher levels of Lp A-I, apo A-IV, higher plasma activity of LCAT, and lower
activity of CETP than their apo A-IV 1/1 counterparts (193).  In contrast, Carrejo et al. (195)
examined the apo A-IV 360 gene mutation in 119 subjects with high cholesterol and high
triglyceride levels in whom carotid wall thickness had been assessed.  In these subjects, no effect
of this mutation was noted on apo A-I, apo C-III, apo A-IV levels, neither on HDL-C and other
lipid variables.  Their results as well as our own and several others (191,192,194,196,198,300-
302) are consistent with the concept that genetic variations within the apo A-IV gene at codon
360 are not significant factors when it comes to variation within apolipoproteins or HDL-C levels.
Although our sample size, at 734, is substantially greater than most of the other studies, we could
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not detect associations between the apo A-IV 360 polymorphism and any of the lipid traits in both
sexes.  Even de Knijff et al. (192), screening 1393 Dutch men as well as the EARS study I (301)
and II (302) investigating students from 11 European countries, did not observe any significant
effect of the 360 polymorphism on various lipid phenotypes.  However, in the EARS studies, they
did not differentiate between males and females, which we feel is essential due to the different
lipid profiles, and therefore, their different susceptibility to gene variation and cardiovascular
disease.
With regard to the apo A-IV 347 threonine (T) to serine (S) mutation very few studies have been
published, and the literature and their results are controversial as well (Table 4).  While some
reports detected an association of the rare S-allele with lower concentrations of apo B (197), total
(298) and LDL cholesterol (197,298), others noted significantly increased levels of apo B
(302,303), total (302) and LDL cholesterol (303), and triglyceride (302) next to elevated BMI
and waist/hip ratios (302) in subjects carrying the S-allele.  This study, however, investigating
more than 700 subjects, is in confirmation with the third group of studies, which did not observe
any effect of the 347 polymorphism on apolipoprotein, lipid, and lipoprotein traits
(195,300,304,305).  However, it is difficult to compare these results due to differences in study
population with regard to ethnic background, age, gender selection, and number of subjects.
Another point of interest was to investigate whether genetic variation at the apo A-IV gene locus
may be responsible for variability on apo A-IV levels.  Previous reports documented decreased
levels in patients with malabsorption syndrome, chronic pancreatitis, and in patients receiving total
parenteral nutrition (306-308), while high levels of plasma apo A-IV levels have been observed in
patients with renal failure (309) and in those with hypertriglyceridemia (310,311).
Genetics also seem to play a role, as an apo A-IV gene deletion, described by Ordovas et al.
(312), resulted in low levels of apo A-IV.  In addition, v Eckardstein et al. (193) reported in
German males that the apo A-IV 360 mutation had an effect on A-IV levels with 1/2
heterozygotes having higher levels than their 1/1 homozygous counterparts.  Several other
investigators (186,195,296,301) including ourselves, however, did not observe such an effect, for
either of the two apo A-IV (360, 347) polymorphisms.  Therefore, the data indicate that, even
though these mutations alter the protein sequence, they do not seem to be responsible for any
variability in plasma apo A-IV levels.
In contrast, the glucose findings are of note.  Data in our study suggest that genetic variation at
the apo A-IV locus affects glucose levels in females.  Women carrying the apo A-IV 1/2 genotype
had significantly higher fasting glucose levels compared to 1/1 homozygotes.
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Figure 16
Similar results have been previously reported by Visvikis et al. (189).  They documented in 158
nuclear healthy families an association of the rare apo A-IV-2 isoform with higher plasma glucose
levels.  Kamboh et al. (190), on the other hand, noted an effect of the apo A-IV-2 allele on higher
fasting insulin levels in normoglycemic and non-insulin-dependent diabetes mellitus (NIDDM)
males.  Verges et al. (296) reported that the potential protective lipid profile found in their control
subjects associated with the apo A-IV 1/2 genotype was erased in NIDDM patients.  However,
the physiological explanation behind these phenomena still needs to be elucidated.  Further
research in this area appears to be warranted to find out whether the apo A-IV 360 polymorphism
affects glucose levels directly or indirectly through hormones such as insulin.
In rats, Uchida et al. (313) demonstrated that the apo A-IV production in hepatocytes was
regulated by several hormones including insulin.  Incubation of these cells with insulin resulted in
an inhibition of the apo A-IV production in a dose-dependent matter.  Furthermore, there is
evidence in rats, that insulin deficiency stimulates the production of VLDL-type triglyceride-rich
particles by the intestine, and causes hypertrophy of the gut, both of which can result in increased
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intestinal apo A-IV secretion (314).  In humans, Attia et al. (315) found higher levels of apo A-IV
in young IDDM patients compared to healthy controls, and noted a close relationship with a
strong glycemic control, as evidenced by strong positive correlation between apo A-IV and
HbA1c.  Similar results were published by Verges et al. (296) who detected higher apo A-IV
levels in NIDDM patients as compared to normoglycemic controls.  Their view was that the
hypertriglyceridemia observed in diabetes is likely to promote the increase of plasma apo A-IV
rather than the opposite.
Another possibility for the apo A-IV 360 effect on glucose levels could be due to either linkage
disequilibrium between this apo A-IV protein polymorphism and another closely linked marker or
an interaction between the apo A-IV type and another unlinked apolipoprotein gene product
(316).
In conclusion, our data are consistent with the concept that genetic variation at codon 360 and
347 within the general population, do not have a direct physiological influence on plasma
cholesterol, triglyceride, LDL or HDL cholesterol levels, the ratio of TC/ HDL cholesterol or apo
A-IV levels, but do affect glucose levels in women.
Lipoprotein Lipase
Lipoprotein lipase is known to be the rate-limiting enzyme in triglyceride catabolism.  In this study
we investigated the lipoprotein lipase Hind III genotype-phenotype interactions.  In addition, by
recruiting a large number of people, we were able to effectively focus on a possible gene-gender
interaction.
The genotype distribution of the Hind III polymorphism in this study was not significantly
different from the Hardy-Weinberg equilibrium and the overall allele frequencies were similar to
previously published studies in Caucasians (208,222,223,228,229,231,232).
In this study, we could demonstrate a significant effect of the LPL Hind III polymorphism on the
variation of plasma concentrations of total cholesterol in women.  The H+ allele was associated
with significantly higher levels of total cholesterol.  Females carrying the wildtype (H+/+) had
significantly higher total cholesterol levels compared to females being homozygotes for the H-
allele (H-/-).  Similar effect on LDL cholesterol was observed in females, with subjects carrying
the H+/+ genotype having the highest and those carrying the H-/- genotype having the lowest
levels (Figure 17).  In males, however, no significant effect was observed for total and LDL
cholesterol.
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The majority of previous studies did not find significant associations between the LPL Hind III
genotype and total or LDL cholesterol (see Table 5).  However, Mattu et al. (226) reported
similar associations of the Hind III H+ allele with total and LDL cholesterol as well as the same
gene-dosage effect with H+ having the highest and H-   having the lowest lipid levels.  Their study
was carried out in a small group containing men only.  In contrast, Heinzmann et al. (208) found a
significant association of the H+ allele with total cholesterol in 189 US Caucasians, but in the
opposite direction.  Individuals carrying the H- allele had higher total cholesterol levels compared
to homozygotes carrying the H+ allele.  With regard to LDL-C, the same trend as total
cholesterol was documented, but did not reach statistical significance.
Elevated plasma LDL-C levels have been accepted as a major risk factor for coronary artery
disease (CAD).  Our result of a positive relationship between the H+ allele and total and LDL
cholesterol may now provide an explanation for previously reported associations of the H+ allele
and CAD (223,226,317,318).  Thorn et al. (223) reported in Caucasians with severe CAD a
significantly higher frequency of the H+ allele compared to healthy controls.  Furthermore, Chen
et al. (317) indicated in their study a significant effect of the Hind III site on carotid artery
atherosclerosis in white males.  Individuals with the H+/+ genotype not only had a significantly
higher average carotid wall thickness, but the H+/+ genotype was also associated with
hypertriglyceridemia and hypercholesterolemia compared to the other two genotypes.  In addition,
patients with type 2 diabetes mellitus and the H+/+ genotype were reported to have the highest
prevalence of CHD (90%) compared with the H+/- (55.4%) and H-/- (54.6%) genotypes,
respectively (319).
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The metabolic mechanism responsible for the association of the Hind III polymorphism with LDL-
C levels is still not completely understood.  It has been suggested that this polymorphic site has an
indirect effect on the LPL activity, with the H+ allele having a lower and the rare H- allele having
a higher LPL activity, respectively.  Since the Hind III polymorphism is located in intron 8 of the
LPL gene, it does not affect the sequence or the gene product.  It is believed that this
polymorphism is in linkage disequilibrium with one or more regions within or in close proximity to
the LPL gene, affecting LPL activity and/or the clearance rate of triglyceride-rich lipoproteins and
their remnants.  In fact, a recent report by Humphries et al. (320) provides strong evidence for
significant linkage disequilibrium between the Hind III site and the LPL S447X mutation.
Recently, it has been convincingly shown that the S447X mutation results in increased LPL
activity (321).  Therefore, individuals with the Hind III site and the LPL wildtype would be
expected to have lower LPL activity.  Our results can also be compared with patients, who are
heterozygous for familial lipoprotein lipase deficiency, and characterized by a 50% reduced LPL
activity.  Brunzell (322) as well as Miesenboeck et al. (323) detected in some of these patients
abnormalities across the lipoprotein density spectrum including an increase in VLDL or
intermediate density lipoproteins (IDL) and small dense LDL particles.  Although, this increase in
LDL is not typical, it might be due to the combined measurement of IDL and small dense LDL in
the total LDL fraction (322).  Furthermore, this alteration in lipoprotein compositions might cause
a reduced affinity of those particles to the LDL-receptor, which could explain the higher LDL
levels.  As suggested before (320) also nonenzymatic effects of LPL, such as its bridging function,
may be more efficient in individuals with the S447 stop mutation.
Concerning HDL-C and triglyceride levels, the results of previous studies are very controversial.
While several investigators demonstrated a relationship between the LPL Hind III polymorphism
and HDL cholesterol and/or triglyceride levels, several others could not verify such an effect (see
Table 5).  Our findings agree with results of the former group.  We could demonstrate a
significant association with the Hind III genotype and HDL-C levels, but in males only (Figure
17).  Those carrying the H-/- genotype had significantly higher HDL-C levels compared with their
H+/+ counterparts.  At the same time, H-/- men had a trend of lower triglyceride values than men
carrying the H+/+ wildtype.  This is in agreement with the concept that the polymorphism is
somehow associated with the LPL activity by finding an inverse relationship between HDL-C and
triglyceride levels.  Our findings confirm previous results (225) suggesting that the H- allele is
associated with a higher LPL activity and the H+ allele is associated with a lower activity.
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In terms of the gene-gender effect, a difference with regard to the LPL Hind III polymorphism
and various lipid traits was noted.  The female population showed significant associations between
the Hind III genotypes and total as well as LDL cholesterol, while men showed a significant effect
on HDL cholesterol.  The reason might be due to differences in hormonal status or other
environmental and lifestyle factors.  Further research is warranted to elucidate the gene-gender
difference.
In addition, it is important to mention, that the data in the publication (see Attachment) was
analyzed differently than in the thesis.  Instead of using baseline data, we evaluated data after
eight days, to ensure a stabilization period for all the subjects.  As a result, the association
between the Hind III polymorphism and HDL-C in men was abolished.  In females, however, the
effect of total and LDL cholesterol became even more significant.
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B. Effects of Apolipoprotein E, A-I, A-IV, and Lipoprotein Lipase
Genotypes on Glucose, Lipid, and Lipoprotein Response to Lifestyle
Intervention
Subjects
Lifestyle intervention with diet and exercise had a significant effect on lowering glucose and lipid
parameters in females and males.  The reduction of each phenotype in percent is demonstrated in
Figure 18.
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These results indicate that the intensive program at the Pritikin Longevity Center is very effective
in lowering cholesterol levels even in a short period of time.  To ascertain what the changes would
have been, had participants been sampled at the two-week time point, a subset of 31 subjects that
participated in the 3 week program was screened (Figure 19).
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As expected, greater reductions were achieved by the 31 subjects versus participants of the eight
day intervention program.  However, comparing our data with results previously published on
over 4000 participants (13) who took part in the same intervention program, but were sampled
after 3 weeks, reductions reported for total and LDL cholesterol were significantly greater at 23%
each as compared to our results at 12.8% and 13.5%, respectively.  One of the reasons for the
greater reduction is the fact, that subjects participated one week longer in the intervention
program compared to our 31 subjects.  The other reason may be the difference in baseline levels
of total and LDL cholesterol.  Their baseline values for total cholesterol compared to ours were
significantly greater at 5.99 mmol/L versus 5.38 mmol/L in males and 6.15 mmol/L versus 5.56
mmol/L in females.  The same was true for LDL-C levels, with males, participating in their study,
having higher baseline levels at 3.90 mmol/L versus 3.21 mmol/L, and females having higher
levels at 3.97 mmol/L versus 3.15 mmol/L, respectively.
Overall, the lifestyle intervention program seems to be effective in lowering various lipid
parameters and therefore, reduce the risk for coronary heart disease.
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The question whether genetic variation at apolipoprotein and lipoprotein lipase gene loci is
responsible for differences in cholesterol lowering response to diet and exercise is discussed in the
following chapters.
Apolipoprotein E Response
Several investigators (20,22,324-326) have previously documented that there is a significant
variability in response to restriction of dietary saturated fat and cholesterol for reductions in
various lipid parameters.  Moreover, others (12,79,80,86-88,90,92,94) have detected that some of
the variability in this response, which is very considerable, may be related to genetic variation at
the apo E gene locus, specifically due to the apo E4 allele, where subjects carrying the apo E4
allele due to an arginine for cysteine substitution at amino acid 112 were more responsive to diet
than subjects without this allele (12,79,80,86,87,94,98).  Conversely, Ordovas et al. (327)
reported that male subjects heterozygous for the apo E2 allele due to an amino acid substitution
of cysteine for arginine at residue 158 are more responsive to HMG CoA reductase inhibitors than
other subjects. Similar results were published in non-insulin-dependent diabetics (NIDDM) (90).
Diabetic subjects with the E2 allele had the greatest response, whereas those with the E4 allele
had the least response after consumption of a “therapeutic diet”.  In this study, we found for the
first time in men carrying the E2 allele a greater response in fasting glucose levels compared to
men carrying the E3/3 genotype or the E4 allele (Figure 20).
As shown in a previous chapter, we presented data demonstrating a significant effect of the apo E
genotype on baseline glucose levels, with females with the E2+ and E4+ allele having lower levels
of fasting glucose compared to the E3/3 wildtype.  The metabolic explanation for the relationship
between apo E and glucose levels as well as response still needs to be elucidated.
Several other studies (76,82-85,87,93,96,100), on the other hand, could not find an association
between the apo E genotypes and lipid traits in response to dietary manipulation, which is in
agreement with our results presented in this study.  We did not observe these effects in lipid
phenotypes, possibly because this was not just an intervention in which saturated fat and
cholesterol were reduced, but also a situation where subjects were encouraged to exercise, they
could restrict their calories, they lost weight, and it was also a diet high in fiber and complex
carbohydrate.  Moreover, in contrast to some previous studies (12,84,87,94,326), it was not
strictly controlled, where the subjects were given all of their food on a metabolic ward and body
weight was maintained.  In this study, these were voluntary participants interested in reducing
their heart disease risk, who paid to participate in this residential program.  Nevertheless, it does
87
represent a large number of subjects who participated in a residential setting in the same diet,
exercise and lifestyle modification program.
Figure 20
Apolipoprotein A-I Response
With regard to the apolipoprotein A-I mutation at -75bp, which is located in the promoter region
of apo A-I gene, the literature has been inconclusive as to whether or not it can affect
transcription of the apo A-I gene (282-284).  The hypothesis here is that, mutations at this gene
locus would be most likely to affect response to HDL cholesterol due to the fact that apo A-I is a
major protein constituent of HDL; however, no significant effects were noted in this regard in this
study.  A previous study (144) in males showed that those carrying the rare A-allele had a
significant increase in total and LDL cholesterol after a fat-rich meal (40%) compared with their
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G/G counterparts.  A more recent study (150) reported that changing from a saturated fatty acid
(SFA) to a polyunsaturated fatty acid (PUFA) diet resulted in a significant greater decrease of
total and LDL cholesterol in women carrying the G/A genotype than in G/G homozygotes.
Responsiveness to a low fat and low cholesterol diet (136,148), on the other hand, demonstrated
that the difference in lipid response between the -75 bp (G/A) genotypes was not statistically
significant.  This is in agreement with our data presented in this study on a larger population.  We
did not observe an effect of the (G/A) mutation in either gender.  It should, however, be
mentioned that the number of subjects, especially for the rarer genotypes, was relatively small,
despite the fact that we studied 734 subjects in total.
With regard to the apolipoprotein A-I genotype at +83 bp, which is located in the first intronic
region of the apo A-I gene, only very little is known.  So far, one previous study (148) on 69
familial hypercholesterolemic patients reported no effect of this mutation on any lipid traits in
response to an NCEP-I diet.  This is in agreement with our results.  We also failed to find an
effect on various lipid phenotypes, especially on HDL cholesterol lowering, which was our
primary hypothesis. However, more research regarding this polymorphism is necessary.
Overall, our data would indicate that neither of those two polymorphisms of the apo A-I gene has
an effect on the response to dietary modifications.
Apolipoprotein A-IV Response
We also examined the effects of the apolipoprotein A-IV 360 genotype.  This is due to a specific
mutation in which glutamine replaces histidine at residue 360 in the apo A-IV gene locus.  Our
data indicate no significant effect of this polymorphism in response to diet, specifically LDL
cholesterol lowering.  Similar results were observed using an HMG CoA reductase inhibitor
(pravastatin) instead of diet (327).  In contrast, other investigators (198,326,238), have
documented that genetic variability at this locus in the heterozygous state, namely the presence of
this mutation, results in reduced responsiveness of LDL-C levels to dietary cholesterol and
saturated fat modulation.  For instance, Mata et al. (328) found in males that the apo A-IV
phenotype modulates the LDL cholesterol lowering response to a diet meeting NCEP Step I
criteria.  Men carrying the apo A-IV-2 isoform had significantly less reduction (7%) than apo A-
IV 1/1 homozygotes (16%).  Similar results were shown by McCombs et al. (198).  They placed a
small group of Caucasians on a high cholesterol diet and found that the apo A-IV-2 allele
attenuates a hypercholesterolemic response.  While the apo A-IV 1/1 group noted an increase of
LDL-C of 19 mg/dl, the apo A-IV 1/2 group only noted one of 1 mg/dl.  Since one of the studies
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only restricted dietary cholesterol, presumably this mutation can affect the response to dietary
cholesterol.  Contrary, others (199) reported a greater responsiveness of HDL-C and A-I levels in
subjects carrying the 2-allele after having switched from a SFA to an NCEP-I diet.  However,
compared to all the previous studies, we provided data on a significantly larger number of
subjects, but we did not observe any effect of the apo A-IV 360 mutation on lipid response in this
study, possibly because so many interventions were carried out at the same time.
The apolipoprotein A-IV 347 mutation, which is a substitution of threonine (T) for serine (S) at
residue 347, is a fairly common mutation in the general population.  The few previous studies on a
limited amount on subjects revealed mixed results.  Jansen et al. (200) documented in 41 males
that carriers of the rare apo A-IV 347 S-allele had greater decrease in total cholesterol, LDL-C,
and apo B when they were switched from a SFA diet to a NCEP-I diet.  In contrast, when those
men were switched again from the NCEP-I diet to a diet rich in monounsaturated fatty acids
(MUFA), they showed a greater increase in total cholesterol and apo B compared to the 347 T/T
wildtype.  In addition, Ostos et al. (201) recently reported in 50 males subjected to an vitamin A
fat load, that those with the S-allele had lower postprandial response in total triglyceride (TG),
large triglyceride rich (TRL) TG, and small TRL-TG, and a higher response in large TRL apo A-
IV and apo B-100 levels than in subjects homozygous for the T-allele.  This would also indicate
an involvement of this polymorphism in the variability of LDL cholesterol response after
consumption of a high saturated fat diet.  However, one has to consider that all those studies were
performed on a limited number of subjects as well as in males only.
In contrast, data of this study, including more than 700 subjects, revealed no significant effect of
this mutation on dietary response, except in females where subjects homozygous for the mutation
(S/S) had a significantly greater reduction in HDL cholesterol at 16.7%, versus 8.6% in females
homozygous for the T-allele (Figure 21).
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These results, however, must be interpreted with extreme caution, because when one carries out
multiple analyses, as we did in this study, one can find associations by chance.  It should be noted,
however, that our a priori hypothesis was that apolipoprotein A-IV mutations would be most
likely to affect HDL cholesterol response, because apolipoprotein A-IV is a protein constituent
not only of triglyceride-rich lipoproteins, but also HDL.
Lipoprotein Lipase Response
Lipoprotein lipase is the major enzyme responsible for triglyceride hydrolysis.  Patients with a
decreased lipoprotein lipase activity due to various mutations in the lipoprotein lipase gene can
develop marked hypertriglyceridemia and an increased risk of pancreatitis.  Our hypothesis was
that alterations in the lipoprotein lipase genotype due to the Hind III locus might affect
responsiveness with regard to triglyceride lowering.  Indeed, subjects heterozygous or
91
homozygous for the rare Hind III restriction site showed a greater responsiveness.  Males
heterozygous for this mutation (H+/-) had a 16.7% reduction in triglycerides versus the males
without the mutation (H+/+) who had only a 7.3% reduction.  However, because of the wide
variability in triglyceride response, these reductions did not achieve statistical significance, either
in men or in women.  However, HDL cholesterol reductions of 9.0% in heterozygous females
(H+/-) were noted to be significantly greater than the reduction of the 5.6% seen in women
homozygous for the common H+ allele (Figure 22).
Figure 22
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As the effect of LPL on HDL particles is indirect via the transfer of surface components from
triglyceride-rich lipoproteins to the HDL fraction, it is likely that the variation in HDL response to
diet is due to the genetic variation at the Hind III gene locus.  A previous study (233) also
documented an effect of this polymorphism on response.  Switching from a SFA to a PUFA diet,
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individuals with the H+/+ genotype had significantly smaller change in total cholesterol (9.3%)
than those with the rare H- allele (14.4%).  Contrary, another study (234) presented in subjects
carrying the H+/+ genotype a greater reduction of VLDL triglyceride and apo B levels than
carriers of the H- allele in response to a 25% restriction in energy intake.  Therefore, to clarify
whether or not this LPL polymorphism has an effect and on which lipoproteins, further research is
necessary.
While dietary intervention and exercise are the cornerstones of therapy for heart disease risk
reduction in order to favorably modify both plasma lipoproteins, glucose, and blood pressure, and
induce changes in body weight, it is well known that there is striking variability in response to
such diets and such lifestyle intervention (12).  It should, however, be stated that another major
factor in regard to responsiveness may be related to compliance, especially in an ad libitum
setting, where body weight changes considerably from one individual to another, and where
subjects are allowed to eat as much or as little as they want.  On the other hand, it is virtually
impossible to do metabolic ward studies on over 700 individuals, to assess the genetic response.
In this intervention, we see that despite the fact that it was a two-week intervention, the effects on
plasma lipoproteins, by the nature of the program, were only assessed at one week.  Even so, the
one-week assessment did indicate significant reductions in total and LDL cholesterol.  However,
we were not able to clearly relate any of the apolipoprotein genotypes or lipoprotein lipase
genotype to this responsiveness.  We did note that apo E genotype clearly affected responsiveness
to glucose in men, and this is an observation that deserves further follow-up, both in population
studies as well as in carefully controlled metabolic ward studies, to determine how apo E
genotype might affect response with regard to glucose lowering.  It is known that subjects with
the apo E2 allele have impaired uptake of chylomicron remnants by the liver, and this might make
them more sensitive to restriction of dietary calories and fat, so that less fuel would be taken up
by the liver, and consequently it might affect glucose homeostasis.
In conclusion, the over-all data indicate that this lifestyle intervention program can have a
significant effect in modulating heart disease risk factors by reducing lipid and lipoprotein levels,
and that within the context of such a broad-based intervention, genetic variability at the various
gene loci investigated in this study, plays only a modest role.
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C. Effects of a Lifestyle Intervention on Plasma Levels of Glucose, Lipid,
and Lipoproteins:  A Long-Term Follow-up
After having demonstrated that this diet and exercise program had a significant effect on short-
term response, it was of interest to investigate the long-term effect as well.  Therefore, data were
obtained from a subset of 202 females and males.  Those subjects participated in the program at
the Pritikin Longevity Center on two different occasions, with a mean time span of 1.7 years
between visits.  Concerning the short-term response, similar results as described for the whole
group were found in this subset of 95 females and 107 males.  Each intervention resulted in a
significant reduction of all lipid parameters in females and males, respectively (Figure 23).
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These data are consistent with the concept that an intensive and controlled diet and exercise
program can be very effective in lowering lipid levels, which has been discussed in detail in the
previous chapter.
Regarding the long-term response, however, no lasting effect was noted in females and males.
Baseline levels at return (Baseline 2) were similar to baseline levels at the initial visit (Baseline 1),
as shown in Figures 24 and 25.
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Figure 24
Figure 25
In females, we noted a trend of higher total and LDL cholesterol levels, and lower glucose and
triglyceride levels at baseline 2 compared to baseline 1.  Levels of HDL-C, however, were
significantly increased at time point 2 (Figure 26).
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Figure 26
In males, comparison of baseline 1 with baseline 2 revealed that levels of total, LDL-C, and HDL-
C were significantly higher, and levels of glucose and triglyceride were non significantly lower
(Figure 27).  These results indicate that in these subjects, the benefits achieved in the short-term,
were not sustained.
Similar results were published by several investigators (329-333).  Bae et al. (329) detected in 120
men and women with hypercholesterolemia, that modest reductions achieved after 6 weeks of a
Step I diet intervention, did not result in further reductions after 18 weeks.  Rather, there was a
trend to return or even exceed baseline levels.  Furthermore, Henkin et al. (331) noted in 73
subjects who received intensive education on the Step I diet during an initial 12 week period, that
levels of plasma cholesterol (19%), HDL-C (8%), LDL-C (16%), and VLDL (66%) had
significantly increased after a 6 months follow-up.  Another study (334) did not find an effect of
either Step I or Step II intervention on LDL-C lowering in men and women, unless subjects
engaged in aerobic exercise in addition to the diet.  Even meta-analyses, carried out by different
investigators (332,333) documented negative effects.  Ramsey et al. (332) presented data on 16
controlled trials of six months to ten years duration.  Their conclusion indicated that the response
of the Step I diet was too small to have any value in the clinical management of lowering serum
cholesterol levels in adults.  Similar results were recently published by Tang et al. (333).  They
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demonstrated in an overview of 19 controlled trials, including 28 comparisons, that in free-living
subjects only modestly reductions of cholesterol concentrations were observed.  Subjects
following the Step I lowered cholesterol concentrations by about 3%, and an additional 3% were
achieved with diets that are more intensive.
Figure 27
There may be multiple reasons for the lack of long-term compliance.  In general, factors such as
biological nonresponsiveness or inadequate knowledge and understanding of the dietary principles
can be a possible explanation.  Moreover, pre-existing restricted diets as well as subject fatigue to
the prudent diet may be another cause.  In addition, accuracy of the food questionnaires filled out
by the subjects may have an influence on results.  One of the major reasons, however, may be the
lack of continuous support and dietary advice from medical practitioners and dietitians.
Concerning our study, other explanations may apply for the failure of long-term response.
Participants in this study were not recruited into a long-term intervention trial.  The majority of
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been to enjoy themselves, while improving their health at the same time.  Thus, they may have not
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had all day to focus on their diet, body, and mind, while there.  To implement and pursue such
intensive lifestyle modifications in the free-living state, however, may be unrealistic.  The diet
changes alone consisted of drastic reductions of daily fat to less than 10% and daily cholesterol to
less than 100 mg.  Therefore, even small trends to return to more usual fat and cholesterol intakes
would result in increased lipid parameters.  In addition, to maintain the intensity of the exercise
program every day may be difficult to fit into a working schedule.  Another reason may have been
that subjects were not supported or supervised by physicians and dietitians once they left the
center.  Thus, motivation and compliance to continue these changes may have declined after a
period.  There is also the possibility that only those subjects returned to the center who were not
able to adhere to the lifestyle changes in the free-living state.
In contrast to those negative results, effective long-term diet intervention studies have been
documented in the literature as well (13,335-340).  Barnard (13), for instance, demonstrated in an
earlier study on 29 subjects, attending the same Pritikin program, that levels of total and LDL-C
after a 12 months follow-up were still significantly lower compared to baseline levels before
intervention.  Other investigators published various long-term responses on lipids, ranging from
moderate changes of 3-6% in young children (337), to 5-7% in subjects from the UK (339), to
15% in men adhering to a Mediterranean diet (338), to 37% reduction in 333 heart disease
patients (336).  In addition, a recent meta-analysis by Yu-Poth et al. (341) included 37 dietary
intervention studies in free-living subjects ranging between 3 weeks and 4 years duration.  They
described an effective lipid response to the Step I and II diets.  The Step I diet was reported to
lower total and LDL-C, triglycerides, and TC/HDL-C ratio by 10%, 12%, 8%, and 10%,
respectively.  The Step II diet reduced those levels by 13%, 16%, 8%, and 7%, respectively.
HDL-C levels, however, were also reduced by 7% after the Step II diet.  In addition, they
documented an even greater reduction of total and LDL-C without a decrease in HDL-C, when
subjects were exercising at the same time.  This beneficial effect of exercise on HDL-C levels,
which was mentioned before by Stefanick et al. (334), was mainly due to weight loss.  Thus, their
recommendations for effective intervention programs include diet modifications, exercise, and
weight control to achieve maximal CHD risk reduction.
Overall, it has to be mentioned that all those meta-analyses need careful interpretation, as the
studies included differed greatly in their design, population, gender, type of diet, duration and
intensity of intervention, as well as in cholesterol response.  Further research is warranted to study
the effects of diet and exercise interventions in a large population in the free-living state, but in a
well supported and controlled environment.
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In conclusion, it appears that the long-term success of cholesterol lowering therapies aimed to
reduce CHD risk depends on the administration of an intensive lifestyle modification program
including, in addition to diet, exercise and weight loss.  Even more important for this goal is the
continuous support and advice of practitioners and dietitians to monitor and motivate participants.
Therefore, my suggestion would be to support people that are at high CHD risk, in a group
setting on a community basis.  An ideal setting would be a community center which includes
exercise facilities, and is operated by a team of physicians, nutritionists, dietitians, nurses,
psychologists, social workers, and exercise physiologists.
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Conclusions
The following conclusions can be drawn from this study of 734 females and males who served as
subjects for this research and who also entered into the Pritikin Longevity Center dietary and
lifestyle program.
Conclusion # 1:  Genetic variation at the various gene loci had different effects on baseline
glucose and lipid levels in females and males.  The same was true regarding the gene-gender
interaction and response to lifestyle intervention.  However, the general reduction of lipids in
response to dietary and lifestyle intervention was not significantly different between genders.
Conclusion # 2:  Apolipoprotein E genotype had a significant effect on plasma apo E, total
cholesterol and LDL cholesterol levels and in females on HDL cholesterol levels, as well as
plasma glucose.  Subjects carrying the apo E4 allele had the lowest plasma apo E levels and the
highest LDL cholesterol levels, while subjects carrying the apo E2 allele had the lowest LDL
cholesterol levels and the highest levels of apo E.  This was true for both men and women.
Conclusion # 3:  Apolipoprotein A-I -75 bp genotype was observed to have a significant effect
on levels of apo B, total and LDL cholesterol in women.  Females carrying the rare A-allele had
higher levels than women carrying the G/G genotype.  The apo A-I +83 bp genotype was noted to
have significant effects on total cholesterol and apo A-I levels in men, such that the presence of
the rare M2- allele was associated with higher levels of apo A-I in the plasma than the more
common M2+ allele.  We also detected linkage disequilibrium between those two polymorphic
gene loci.
Conclusion # 4:  Apolipoprotein A-IV 360 genotype had no significant effect on any biochemical
parameters, except for glucose levels in females.  Women with the 2-allele had significantly higher
fasting glucose levels compared to women with the 1/1 wildtype.  Therefore, these data indicate
some association of apolipoprotein A-IV genotype and glucose metabolism in females.
Conclusion # 5:  Lipoprotein Lipase Hind III polymorphism was noted to have a significant effect
on total and LDL cholesterol in females, and a significant effect on HDL cholesterol in males.  In
females, the presence of rare H- allele resulted in decreased levels of total and LDL cholesterol,
especially when it was represented in the homozygous state.  This was not observed in men.  In
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men, however, the presence of the rare H- allele was associated with an increase in HDL
cholesterol levels.
Conclusion # 6:  The effects of the lifestyle intervention program, i.e. restriction of total fat,
saturated fat, and cholesterol, coupled with an exercise program in this residential Center, resulted
in significant decreases in total cholesterol, LDL-C, HDL-C, triglycerides and body weight in both
men and women over an eight day period.  No significant effects of genotype were noted on the
response of these variables, except that the presence of the apo E2 allele in men appeared to cause
an enhanced glucose lowering, the presence of the apo A-IV 347 rare S-allele in the homozygous
state resulted in excess in HDL cholesterol lowering in females, and the presence of the rare H-
allele of lipoprotein lipase Hind III, either in the heterozygous or homozygous state, appeared to
result in excess HDL cholesterol lowering in females.  Moreover, when effects of this lifestyle
intervention were examined comparing the eight day data with the fourteen day data, additional
reductions were observed from the end of week one to the end of week two.  By the end of week
two, substantial greater reduction of HDL cholesterol was observed.
Conclusion # 7:  This intervention does not appear to result in any lasting benefit when the
subjects are in the free-living state and then return to the Center for another intervention program,
because at their base line levels for men, the LDL cholesterol levels were in fact approximately
6% higher than at the first baseline for men, and virtually unchanged for women.  These data are
consistent with the concept that this intervention results in no lasting change, certainly for LDL
cholesterol.  A better intervention for people would be to incorporate lifestyle modification into
the free-living state, possibly as part of a group approach, where people get regularly supported
and monitored on a community basis.
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Limitations
A major limitation of this study:
1. Taking blood samples at the eight day point is less than optimal.  Our original plan was to
have received samples from two or three week points, where response to the lifestyle
intervention would have been greater.  As part of this protocol, however, only samples
were obtained at the eight day point for the vast majority of subjects, because patients
were discharged prior to the blood drawing day on the two week program.  This
represents a significant limitation in our ability to determine whether the genotypes really
had an effect on responsiveness.
2. This study was not just a change in dietary content, but also resulted in decreased caloric
intake and body weight.  In addition, there was an exercise component, so that this
intervention was not a pure dietary modification under a controlled iso weight situation,
which other studies have done in the past.  On the other hand, the advantage of this
approach is that we could look at large numbers of subjects, who all went through the
exact same lifestyle modification program and all the food was provided by the Center.
3. Another concern is that a large number of subjects had medical conditions, which are
normally excluded from studies.  Even though we adjusted for all those factors in the
analyses, they still may have affected our results.  However, including these subjects may
be a more realistic approach to study these effects in a middle-aged and elderly population.
4. The last concern is regarding our conclusion about long-term effects of this diet and
lifestyle intervention.  It is possible, that subjects who returned for a second intervention
program may have been those individuals who were no longer complying with the
program.
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Summary
Aims of the Study
The first aim of this study was to investigate the effects of apolipoprotein (apo) E, A-I, A-IV, and
lipoprotein lipase genotypes on various plasma apolipoprotein levels as well as on serum total,
low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol,
triglyceride, and glucose values in 734 middle-aged and elderly female and male subjects.  The
second aim was to study the effect of a short-term lifestyle intervention program, including diet
and exercise, on glucose and lipid response as well as the results of a long term follow-up.
Methods
Polymerase chain reaction (PCR) and restriction isotyping were used to examine the presence of
restriction fragment length polymorphisms (RFLP´s) at the various gene loci.
Results
The allele frequencies for all polymorphisms investigated were similar to those reported in other
studies for Caucasians.  After adjustment for age, body-mass index, medications, alcohol use, and
smoking, apo E genotype was noted to have significant effects on apo E, total cholesterol, LDL
cholesterol, and glucose levels in females, and on apo E, LDL cholesterol, and HDL cholesterol
levels, as well as on the total cholesterol (TC)/ HDL ratio in males.  Female and male subjects
with the apo E4 allele had significantly (p<0.05) lower plasma apo E (25 and 15%) and higher
LDL cholesterol levels (5 and 2%), while those with the apo E2 allele had significantly (p<0.05)
higher apo E (32 and 27%) and lower LDL cholesterol levels (10 and 10%) than the apo E3/3
group.  Moreover, female apo E4 carriers had significantly (p<0.05) lower glucose values (11%)
than the apo E3/3 group.  With regard to response, we observed for the first time, that the apo E
genotype had a significant effect on glucose levels in males, with those carrying E2 allele having a
greater response (-10.6%) compared to apo E3/3 (+0.8%) men, and those carrying the E4+ (-
3.7%) allele.  These data are consistent with the concept that, in addition to the well known
effects of apo E genotype on LDL-C values, this locus plays a significant role in modulating
plasma apo E levels and plasma glucose response to behavioral intervention.
Concerning the apo A-I -75 bp polymorphism in the promoter region and +83 bp polymorphism
in the first intron of the apo A-I gene, significant associations were found for the -75 bp mutation
in females only.  Women carrying the rare A-allele had significantly (p<0.05) higher levels of apo
B (5%), total (4%) and LDL cholesterol (6%), as well as a higher TC/HDL ratio (6%) compared
to women carrying the G/G genotype.  For the recently detected +83 bp mutation, we found a
significant raising effect (p=0.002) of the rare M2- allele on apo A-I in men, and a weaker raising
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effect (p<0.05) on total cholesterol in men and women, respectively.  Furthermore, a linkage
disequilibrium (p=0.037) was found between the two polymorphisms.  Males carrying the G/G
M2+/- haplotype had the highest apo A-I levels (p=0.021) compared to all the other haplotypes.
Therefore, these data indicate an association between the -75 bp allele and factors regulating
LDL-C metabolism.  However, no interactions between these apo A-I genotypes and HDL
cholesterol levels, as well as lipid response to diet and exercise were observed.
Concerning the apo A-IV 360 and 347 polymorphisms, no significant effects on any lipid traits
were noted in females and males.  However, in females, a significant association (p=0.004) was
observed with glucose levels, with women carrying the rare 2-allele having higher levels (11%)
compared to the 1/1 genotype.  In response to lifestyle intervention, females with the apo A-IV
347 S/S genotype had significantly greater reduction in HDL-C (16.7%) versus females
homozygous for the common T-allele (8.6%).  These results indicate that the apo A-IV 360 and
347 mutations have some effect on lipid metabolism in these subjects.
The lipoprotein lipase Hind III genotype was noted to have a significant effect (p<0.05) on total
and LDL cholesterol in women and on HDL cholesterol levels in men.  Women being
homozygous for the rare H- allele had significantly lower levels of total and LDL cholesterol (4%
and 4%) than women being H+/+ homozygotes.  In men, those carrying the H- allele had
significantly (p=0.003) higher HDL-C levels compared to the H+/+ genotype.  However, with
regard to the lifestyle intervention, females heterozygous for the H- allele had significantly greater
reductions in HDL-C (-9.0%) compared to females homozygous for the H+ allele (-5.6%).
Therefore, this data suggest that in females, the rare H- allele has a cholesterol lowering, and
therefore potentially cardioprotective effect, which seems to be offset by HDL cholesterol
lowering during diet and exercise intervention.
A long-term follow-up was carried out on a subset of 202 females and males who attended the
program at two different occasions.  The analysis of these data revealed no long lasting effect of
the short-term intervention program.  When subjects returned to the Pritikin center after a mean
time span of 1.7 years, their baseline lipid levels at visit 2 were similar or even slightly exceeded
the levels at baseline 1.  These data shows that it is difficult for free-living subjects to implement
and comply long-term with the intensive lifestyle changes carried out short term under carefully
monitored conditions.
Conclusion
These results show that some of the candidate gene loci examined have a major impact on lipid
and glucose levels, whereas others play a minor role.  Concerning lipid lowering response to diet
and exercise, the gene loci investigated were not significantly associated with individual variability
in response in this particular experimental design.  Our data shows that diet and exercise should
remain the cornerstone for the reduction of CHD risk factors.  The challenge is how to achieve
long-term compliance to successful short-term intervention programs.
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